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Abstract 
Introduction: Type II Diabetes Mellitus (T2DM) is a non-communicable disease 
associated with chronic low-grade inflammation and persistent activation of the acute 
phase response (APR). Serum amyloid A (SAA) is one of the proteins of the APR and has 
previously been shown to induce amyloidogensis in fibrin(ogen) ex vivo. The impact of SAA 
on the haematological and its amyloidogenic potential in T2DM has however yet to be 
determined. Further to this, literature has noted the ability of various molecules to “mop” 
and reverse fibrin amyloid formation, thus identification of a molecule able to “mop” SAA’s 
haematological impact would be highly beneficial in future. 
Aim:  To quantify SAA levels in T2DM before determining the impact of this molecule on 
the haematological system. Further to this, determining the amyloidogenic potential of SAA 
in this disease state. Finally, the study aims at determining whether high-density lipoprotein 
(HDL), lipopolysaccharide-binding protein (LBP) or the combination of these two molecules 
are effective SAA mopping agents. 
Methods: The blood of 75 participants (n=36 control participants, n=39 T2DM participants) 
was collected and analysed for both quantitative and morphological markers. Quantitative 
markers include: inflammatory biomarker profiling and thromboelastography whereas the 
morphological markers include: whole blood scanning electron microscopy, fibrin clot 
scanning electron microscopy and fibrin clot confocal microscopy. Additionally, a control 
study was performed where SAA, HDL and LBP were incubated in the whole blood ex vivo 
before being analysed for these measurable and morphological markers. Lastly, an 
experimental study was performed whereby the efficiency of the mopping agents was 
tested ex vivo in T2DM whole blood. 
Results: SAA was found to be significantly elevated (p < 0.0001), 10-fold, in T2DM and 
induced platelet hyperactivation and agglutination. Furthermore, this study confirms that 
SAA is indeed amyloidogenic in nature. Qualitative SEM fibrin analysis showed that SAA 
induced the formation of dense matted amyloid deposits in the fibrin fibres. This was 
confirmed quantitatively when confocal microscopy, using amyloid specific stains, showed 
SAA induced a significant (p = 0.0452 and p = 0.0062) increase in amyloid signal in two of 
the three fluorescent markers. HDL and LBP proved to be ineffective SAA mopping agents. 
Conclusion: SAA is indeed amyloidogenic in nature and is contributing to the abnormal 
fibrin formation observed in T2DM. Despite this however, T2DM is a complex disease 
whereby various molecules and physiological mechanisms are altered. Thus, attributing 
the numerous haematological changes to a singular molecule is unfitting. Consequently, 
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the use of a single molecule targeting “mopping” agent to reverse or inhibit these 
haematological alterations seems impractical. 
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1.  Introduction  
 
In recent years, a change in the global disease burden from communicable to non-
communicable diseases has been observed. Cardiovascular diseases (CVD) alone 
accounts for up to 17.7 million deaths each year (World Health Organisation, 2018). 
Furthermore, the prevalence of Diabetes Mellitus, one of these non-communicable 
diseases, is ever growing (Mathers and Loncar, 2006). In 2015 it was estimated that over 
400 million people worldwide suffered with Diabetes Mellitus, this number has been 
estimated to rise to approximately 650 million people by 2040 (IDF, 2018, World Health 
Organisation, 2017). Importantly, all non-communicable diseases are linked to chronic low-
grade inflammation. 
 
An acute inflammatory response is generally considered as a beneficial protective 
mechanism of the body in response to injury, infection or trauma. In contrast however, the 
chronic low-grade inflammation associated with non-communicable diseases produce 
extensive harmful effects on the body. Specifically, the haematological system is constantly 
exposed to the circulating inflammatory mediators which produce profound detrimental 
effects on all of the bloods components (Pretorius et al., 2016b). The hallmarks of this 
subsequent inflammatory profile in the blood, cause the blood to become more prone to 
clotting (hypercoagulable) which are broken down less effectively and efficiently 
(hypofibrinolysis) (Kell and Pretorius, 2015). Various inflammogens such as Interleukin 1β 
(IL-1β), IL-6, C-reactive protein (CRP) and Tumor necrosis factor-α (TNF-α) are 
upregulated in the various non-communicable diseases and consequently induce the 
hypercoagulable and hypofibrinolysis state within the haematological system (Salini et al., 
2011, Pickup, 2004). In addition to these two hallmark effects, the upregulated pro-
inflammatory associated cytokine-peptide hormone signals further induce the synthesis of 
a family of acute phase proteins, known as Serum Amyloid A (SAA), from the liver (Pickup, 
2004, Badolato, 1994). Although SAA serves a natural function in the maintenance of 
homeostasis, the proteins’ function is altered in chronic inflammation (Ye and Sun, 2015). 
This alteration is due to both a considerable increase in the protein concentration levels as 
well as the increased amount of the various other pro-inflammatory molecules which further 
contributes to a vicious positive feedback-loop (Uhlar and Whitehead, 1999). 
 
An increase in concentration of circulating SAA and pro-inflammatory cytokines has also 
been associated with the presence of lipopolysaccharide (LPS), which is another molecule 
associated with chronic low-grade inflammation (Guo et al., 2013). The LPS molecules 
originate from cell wall components of all gram-negative bacteria which exist in the 
haematological system as dormant bacteria (Hurley, 1995, Kell and Pretorius, 2018, 
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Pretorius et al., 2017a, Pretorius et al., 2018a, Pretorius et al., 2016a), or as a constant 
replenishment into the blood system, possibly as a result of the individual suffering from 
leaky gut or gut dysbiosis(Sylvia and Demas, 2018, Saltzman et al., 2018, Kurita et al., 
2017, Slyepchenko et al., 2016). This LPS is then shed from the circulating bacteria into 
circulation which causes various downstream impacts on the haematological system 
(Pretorius et al., 2018a, Pretorius et al., 2016a). 
 
Type II Diabetes Mellitus (T2DM) is a known inflammatory disease, also associated with 
gut dysbiosis (Slyepchenko et al., 2016), consequently one could expect the levels of 
circulating SAA and LPS to be elevated. In literature, this hypothesis has been confirmed 
in various studies. Kumon et al. (1994) observed that individuals presenting with Non-
Insulin-Dependent Diabetes Mellitus had significantly higher levels of SAA in comparison 
to healthy age matched controls. Additionally, Marzi et al. (2013) found further evidence to 
support the hypothesis of increased circulating SAA levels, in relation to T2DM, as they 
observed a significantly greater concentration of circulating acute-phase SAA in diabetic 
patients in comparison to the age matched healthy control individuals. 
 
As previously stated, one of the hallmarks of inflammation is a hypercoagulable state as a 
result of pathological fibrin(ogen), caused by, amongst others, circulating SAA and LPS 
(Page et al., 2019, Pretorius et al., 2016a). Previous research has shown that during 
inflammation, fibrin(ogen) becomes amyloidogenic. This occurs through a conformation 
change in the protein fibrin fibre structure, from a predominately α-helix configuration into 
β-sheet dominant structure (Kell and Pretorius, 2016). (Pretorius et al., 2017b)(Pretorius et 
al., 2017b)Further studies also showed that in T2DM, a state of amyloidogenesis in 
fibrin(ogen) exists, which is observed via the hypercoagulable state of the blood (Pretorius 
et al., 2017b). Consequently, it is suggested that LPS might be the amyloidogenic 
inflammagen that is the causative agent in the hypercoagulability noted in T2DM.  
Additionally, Pretorius et al. (2017a) previously noted that this amyloid state in T2DM could 
be substantially removed with the use of mopping agents such as LPS-binding protein. 
Despite the drastic improvement when using LPS-binding protein, some amyloid signal 
remained. Due to this observation (Pretorius et al., 2017a), as well as the presence of other 
inflammatory cytokines, and inflammagens, such as SAA, one could also assume that SAA 
greatly influences this process of amyloidogenesis in T2DM. 
 
Considering this knowledge, the questions then arise as to the amyloidogenic potential on 
fibrin(ogen) of SAA in T2DM, and whether SAA can be used as an effective (circulating) 
marker in T2DM. Furthermore, determining whether one could use a specific SAA mopping 
agents in conjunction with LPS-binding protein, for the total removal of amyloid signal in 
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both a healthy fibrin(ogen) plasma model incubated with SAA as well as in naïve T2DM 
plasma. 
 
Consequently, the following paragraph formulates this protocol’s hypothesis: 
 
Hypothesis: Healthy plasma incubated with exogenous SAA added will results in a 
significant amyloid signal, which can then be removed with the addition of LPS-binding 
protein, HDL and a combination of the two molecules. Additionally, in T2DM we will observe 
increased amyloidogenic signal in plasma as well as an increased presence of circulating 
acute-phase SAA and circulating pro-inflammatory markers. The addition of LPS-binding 
protein, HDL and the combination will remove significant amyloid signal in plasma of T2DM. 
 
Following this hypothesis, the following aim and objectives will therefore direct this thesis: 
 
The aim of this study is to investigate the amyloidogenic potential of SAA and determine 
the effectiveness of HDL and LBP as amyloid mopping agents in the haematological 
system in T2DM.   
 
The first objective of this MSc is to determine the levels of SAA found in T2DM individuals 
and determine quantifiable and morphological differences in the haematological system of 
age matched control and T2DM individuals. 
 
The second objective of this MSc is to determine whether exogenous SAA can in fact 
cause amyloidogenesis when added to control whole blood and platelet poor plasma, and 
whether its amyloid actions can be negated using the mopping agents HDL and LPS-
binding protein. 
 
The third objective of this MSc is to determine whether quantifiable and morphological 
alterations observed in whole blood and platelet poor plasma of T2DM can be reversed 
using HDL and LPS-binding protein. 
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2. Literature Review 
 
2.1 Epidemiology of Diabetes Mellitus 
 
Diabetes Mellitus (DM) represents an ever-growing global health and economic burden. It 
was estimated that every minute that passes, six people die as a result of the disease 
worldwide (Wild et al., 2004). A Zheng et al. (2017) study, showed that the prevalence of 
DM has quadrupled over the last three decades, with almost 90% of all diabetes cases 
being that of Type II Diabetes Mellitus (T2DM). Furthermore, the 2017 study showed that 
globally, one in every eleven adults between the ages of 29 and 75, suffer from T2DM. In 
2010 alone, DM was estimated to have caused approximately 3.96 million deaths in the 
adult population, this equates to 6.8% of the global mortality in 2010 (Roglic and Unwin, 
2010). This figure rose to an estimated 5 million deaths in 2015 due to DM and the 
conditions associated complications, which is equivalent to a death caused by DM every 
six seconds (IDF, 2018). 
 
The prevalence of T2DM is more apparent in low to middle-income countries such as “third 
world” countries. South Africa is no different, with T2DM placing a huge socio- and 
economic burden on the country. In 2009, 2 million people (representing 9% of the 
population) over the age of 30, suffered from DM (Bertram et al., 2013), a prevalence that 
has almost doubled from 5.5% in less than a decade (Bradshaw et al., 2007). The rapid 
rise in the prevalence of this non-communicable disease can be attributed to various 
factors such as the phenomenon of population ageing, economic development, 
urbanization, a transition to westernized dietary eating habits as well as the increase in 
sedentary lifestyles (Bruno et al., 2005, Holman et al., 2015, Vorster et al., 2005, Steyn et 
al., 1997). The combination of a sedentary lifestyle and a move towards the energy dense 
westernized diet results in obesity, one of the leading risk factors and comorbidities of 
T2DM (Eckel et al., 2011). Adiposity, with specific regard to intra-abdominal adiposity, 
poses the greatest risk in developing DM (Cnop et al., 2002).  Importantly, in 2013 in South 
Africa it was estimated that approximately 38% of men and 69% of women were overweight 
(Ng et al., 2014), with Joubert et al. (2007) attributing 87% of all DM cases in South Africa 
to excessive body weight. It was estimated in the Global Burden of Disease study (2016) 
that the second and third leading risk factors resulting in premature death and disability in 
South Africa are high body mass index and hyperglycaemia respectively.  
 
DM is associated with various microvascular and macrovascular complications (Fowler, 
2008) which places a further burden on the South African health system (Pheiffer et al., 
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2018). In a study by Bertram et al. (2013), it was estimated that DM annually causes 
approximately 8000 new cases of blindness and 2000 new cases of amputations. 
Additionally, Bradshaw et al. (2007) reported that DM is the root cause of approximately 
14% of cases of ischaemic heart disease, 12% of hypertensive disease, 10% of stroke and 
12% of renal disease. 
 
It is evident that DM is a huge socio- and economic burden globally and more importantly 
in South Africa, and as a result, a new innovative way of approaching diagnosis and 
treatment is essential going forward. 
 
2.2 Aetiology of T2DM  
 
DM is one of the oldest documented diseases known to man as it was first reported in a 
Egyptian manuscript approximately 3000 years ago (Ahmed, 2002). The distinction 
between the two types of DM was first made in 1936 whereby Type I DM (TIDM) was 
referred to as insulin-dependent DM, whereas Type II DM was called non-insulin 
dependent DM. Following on from this in 1988, T2DM was then further described as a 
component of metabolic syndrome (Patlak, 2002). The American Diabetes Association 
(2009) then went on to define T2DM as a group of metabolic diseases which is 
characterized by the presence of hyperglycaemia, insulin resistance and relative insulin 
deficiency. Furthermore, the symptoms present polyuria, polydipsia, polyphagia and 
potentially blurred vision. It is now known that T2DM occurs as a result of an interaction 
between genetic, environmental and behavioural risk factors (Olokoba et al., 2012, Chen 
et al., 2011). 
 
TIDM’s insulin deficiency is a direct consequence of the destruction of insulin-producing β-
cells, found in the islets of Langerhans within the pancreas, due to an autoimmune 
response (Notkins and Lernmark, 2001). In contrast, T2DM begins with initial defective 
insulin functioning which then develops from the subclinical impaired glucose intolerance 
to insulin resistance, until finally overt diabetes (Olokoba et al., 2012). The exact 
mechanism behind this phenomenon is not fully elucidated yet, however various theories 
exist. 
 
Randle et al. (1963) studies introduced the “Lipid Theory” of insulin resistance whereby the 
hyperplasia and hypertrophy of adipocytes occurring in obesity results in an increased 
circulating concentration of free fatty acids (FFAs) within the bloodstream which goes on 
to impair insulin-stimulated glucose oxidation in muscle. The FFAs accumulate within the 
cytosol of striated muscle. This forces the mitochondria to increase fat oxidation which in 
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turn increases the acetyl coenzyme A:coenzyme A and NADH:NAD+ ratios in the 
mitochondria. This alteration inactivates pyruvate dehydrogenase which causes an 
accumulation of citrate in the mitochondria. This, in turn, inhibits phosphofructokinase 
producing a net increase in intramitochondrial concentrations of Glucose-6-Phosphate, 
thus promoting glycogen synthesis and inhibits hexokinase. This cascade effect produces 
high concentrations of intracellular glucose thus preventing any further glucose entry via 
facilitated diffusion through the Glucose Transporter Type 4 (GLUT-4) membrane protein 
(Randle et al., 1963, Samuel et al., 2010). 
 
The “Lipid Theory” was further supported when it was discovered that diacylglycerol, a by-
product of FFA oxidation, activates protein kinase C-theta (PKC- θ) (Schmitz-Peiffer et al., 
1997, Griffin et al., 1999) which in turn causes the Insulin Receptor Substrate 1 (IRS1) 
signalling protein to be phosphorylated on the serine binding site and not the tyrosine 
binding site (Saad et al., 1993). This altered phosphorylation site inactivates the IRS1 
protein effectively inhibiting the activation of Phosphoinositide 3-kinase (PI3K), thus 
negating the normal GLUT-4 translocation to the sarcolemma (Griffin et al., 1999). 
Consequently, fewer GLUT-4 carrier proteins are available on the sarcolemma causing 
reduced glucose uptake by the muscle cells, consequently causing sustained 
hyperglycaemia. 
 
Further studies have been completed which implicate inflammation with hyperglycaemia 
and insulin resistance in the development of T2DM. Shoelson et al. (2006) historical review 
of inflammation and insulin resistance traced this relationship back as far as the 1800s 
where a study showed that a high-dose of salicylates, a group of chemicals with anti-
inflammatory effects found in various foods, appeared to decrease glycosuria in patients 
with DM. This effect was further validated when Reid et al. (1957) showed that a high-dose 
of aspirin, salicylate being the active compound, for individuals presenting with diabetes 
produced improvements in glycemia and, in one of the individuals tested, the 
discontinuation of insulin treatment (Shoelson et al., 2006). 
 
In the early 1990s, research into inflammation and insulin resistance gained traction when 
it was suggested that Tumor Necrosis Factor-α (TNF-α), a cytokine produced by 
adipocytes and therefore overexpressed in obesity, can attenuate local and systemic 
metabolism (Feinstein et al., 1993, Hotamisligil et al., 1993). The effects were attributed to 
the catabolic effect of TNF-α whereby increasing β-oxidation of FFAs, resulting in the 
accumulation of diacylglycerol and other metabolic intermediates, thus tying in with the 
“Lipid Theory”. Furthermore, the increased circulating TNF-α causes the phosphorylation 
and activation of the protein Tyrosine Phosphatase (SH-PTPase), which causes the rapid 
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removal of the tyrosine phosphate group from IRS-1. This process essentially terminates 
the effect of insulin, resulting in a reduction of GLUT-4 translocation to the muscle 
sarcolemma consequently reducing glucose uptake (Engelman et al., 2000). T2DM 
research focusing on adipokines (Monocyte Chemoattractant Protein-1 (MCP-1), 
interleukin-6 (IL-6), resistin, adiponectin, Plasminogen Activator Inhibitor 1 (PAI-1) and 
angiotensinogen), inflammation and insulin resistance then accelerated rapidly in the 
science field (Cefalu, 2009). 
 
The exact physiological event that leads to the initiation of inflammation in obesity is not 
fully elucidated, however, Regazzetti et al. (2009) have recently presented the ‘Hypoxia 
Hypothesis’ that occurs in obesity which eventually results in insulin resistance. Their study 
suggests that the hypertrophied adipocytes, found in obesity, become so large resulting in 
these adipocytes becoming hypoperfused. Consequently, small regional areas become 
hypoxic leading to the increased production and expression of Hypoxia-Inducible Factor-1 
(HIF-1) (Regazzetti et al., 2009, Cefalu, 2009). The increase in circulating HIF-1 from these 
hypoxic regions activates the c-Jun N-terminal kinases (JNK1) and IKK/NFkB pathways as 
well as causing the increased expressions of various genes involved in inflammation and 
endoplasmic reticulum stress. Furthermore, it is suggested that this microhypoxia in the 
adipocytes causes the cytokines (TNF-α and IL-6) as well chemokines (Monocyte 
Chemoattractant Protein 1 (MCP-1)) to initiate the recruitment of macrophages into the 
adipose tissue. These infiltrated macrophages begin the formation of crown-like structures 
which further exacerbates the inflammatory response  (Wang et al., 2007, Hosogai et al., 
2007). 
 
The perpetual hyperglycaemia and impaired insulin signalling previously discussed 
produce an initial phase of hyperinsulinemia whereby the β-cells hypertrophy and increase 
insulin production and synthesis (Regazzi et al., 2014). If this state of continuous 
hyperglycaemia remains long term, β-cell dysfunction occurs resulting in the progressive 
decline in the functioning of these cells leading to β-cell exhaustion whereby the cells are 
unable to produce the required levels of insulin (Cerf, 2013). β-cell dysfunction and death 
are caused by elevated levels of circulating proinflammatory cytokines inducing 
mitochondrial stress (Cnop et al., 2005, Eizirik and Cnop, 2010, Gurgul-Convey et al., 
2011) which then alters the regulation of gene expression involved in impaired insulin 
secretion and increased apoptosis (Gilbert and Liu, 2012).  
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2.3 T2DM and Inflammation 
 
In addition to being involved in the aetiology of the disease, low-grade inflammation 
persists chronically in T2DM (Xu et al., 2003). A study by Menkin (1941) was one of the 
first of its kind through which a firm link between inflammation and diabetes was 
established. The study made use of healthy dogs as well as dogs that had undergone a 
pancreatectomy surgery. An irritant was then injected into the pleural cavity of the lungs 
where after various physiological responses were monitored and studied. No changes were 
observed in the healthy “non-diabetic” control dog group. In contrast, the “diabetic” dogs 
presented with an approximate 85% increase in blood glucose in addition to proteolysis. 
Furthermore, enhanced rates of gluconeogenesis were observed with increased infiltration 
with vacuolized polymorphonuclear cells. The study went one step further when Menkin 
was able to block this inflammatory response via the administration of insulin. The study 
was crucial as it was able to illustrate that inflammation augments the degree of diabetes 
in addition to diabetes enhancing inflammation (Guest et al., 2008). 
 
A Pickup and Crook (1998) study suggested that T2DM was a pro-inflammatory disease 
and involved the activation of the innate immune system. Activation of innate immunity 
induces various systemic inflammatory responses that provide the body’s first line of 
defence against any microbial, physical or chemical insults (Beutler, 2004). The responses 
allow for damage repair, isolation of any microbial infectious threats as well as the 
restoration of tissue homeostasis (Takeda and Akira, 2004). Following the Pickup and 
Crook (1998) study, various studies went on to show that T2DM is in fact accompanied by 
innate immune system activation which induces alterations in the cytokine profile producing 
a shift to a pro-inflammatory state (Medzhitov and Janeway, 2000). Selected pro-
inflammatory cytokines whose circulating levels are altered in T2DM are discussed in the 
following paragraphs. 
 
Interleukin-1β: 
 
Interleukin-1β (IL-1β) is a potent pro-inflammatory cytokine which is crucial for host-
defence in response to any infections and/or injuries (Dinarello, 1996). IL-1β is the most 
prominently studied molecule of the 11 IL-1 family members (Lopez-Castejon and Brough, 
2011). IL-1β is produced and secreted by various cell types although the majority of the 
circulating IL-1β originates from monocytes and macrophages as a result of the activation 
of the innate immune system (Madej et al., 2017).  
 
Briefly, when macrophages or monocytes are exposed to any circulating repetitive 
molecular motifs, named ‘pathogen associated molecular patterns’ (PAMPs), they respond 
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via pattern recognition receptors (PRR’s). These regulate gene expression (Takeuchi and 
Akira, 2010) thus producing an inactive 31 kilodalton(kDa) precursor molecule, termed pro-
IL-1β (Lopez-Castejon and Brough, 2011). Importantly, pro-IL-1β can also be produced in 
response to factors such as activated complement components as well as the presence of 
other inflammatory cytokines such as TNF-α (Madej et al., 2017). These cells are now 
“primed” with pro-IL-1β, so that when they encounter a further PAMP or DAMP (danger 
associated molecular pattern) the inactive pro-IL-1β is cleaved and thus activated by the 
pro-inflammatory protease caspase-1 (Thornberry et al., 1992) via the recruitment of a 
multi-protein complex referred to as the inflammasome (Schroder and Tschopp, 2010). 
This mature activated IL-1β is then able to be rapidly secreted into circulation. 
 
Once secreted, activated IL-1β acts as a ligand and binds to one of two receptors; 
Interleukin- 1 Receptor Type I (IL-1RTI) and Interleukin- 1 Receptor Type II (IL-1RTII) 
(Auron and Webb, 1994). The type I receptors are associated with various cell types such 
as T cells, hepatocytes, fibroblasts and endothelial cells (Essayan et al., 1998), thus when 
ligand binding occurs, these type I receptors transduce IL-1β most extensive biological 
effects (Sims et al., 1993). In contrast, the type II receptor, located on B cells and 
neutrophils, and act as decoy receptors as they are inactive (Peters et al., 2013). The 
binding of IL-1β to these receptors inhibit the transduction of the molecules’ effects, thus 
the IL-1RTII may serve as an anti-inflammatory response system. 
 
Due to the wide range of cell types that IL-1β interacts with, the effects of this cytokine are 
vast. Briefly, IL-1β, when secreted, upregulates intercellular adhesion molecule, such as 
ICAM-1 and VCAM-1, which cause increased endothelial cell adherence of leukocytes 
(Hawrylowicz et al., 1991). Additionally, IL-1β causes the induction of arachidonate 
metabolism which acts as a second messenger in order to induce the synthesis of various 
other cytokines, including TNF and IL-6 as well as acting in a positive feedback mechanism 
to further induce IL-1 release (Vannier and Dinarello, 1994). This cytokine also acts as a 
lymphocyte activating factor whereby IL-1β is required for optimal T-cell activation as well 
as proliferation (Shirakawa et al., 1989). Importantly, the interaction and binding of IL-1β 
with hepatocytes causes the inhibition in the production of various housekeeping proteins 
(eg, albumin) as well as stimulating the synthesis of acute phase response proteins 
(Essayan et al., 1998). This will be discussed in depth further into the literature review. 
 
In T2DM, IL-1β has commonly been reported as one of the main causes of β-cell failure 
(Maedler et al., 2002, Ehses et al., 2007) as the β-cells themselves begin to secrete IL-1β 
when stimulated by increased glucose levels. This increased hepatic IL-1β concentration 
causes increased macrophage accumulation as the cytokine acts as a chemoattractant 
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molecule (Ehses et al., 2007). Eventually, β-cells in the Islets of Langerhans reduce in size 
and mass before undergoing cell death as infiltrated macrophages and IL-1β promote 
various mechanisms that induce necrosis and islet inflammation (Steer et al., 2006) as well 
as β-cell “autocrine apoptosis” (Donath et al., 2003).  
 
Interleukin 6: 
 
Human Interleukin-6 (IL-6) is formed from 212 amino acids, which includes a 28-amino-
acid signal peptide, with its gene which has been mapped to chromosome 7p21 (Tanaka 
et al., 2014). The majority of IL-6 is synthesized by resident macrophages in the local area 
of damage or microbial insult and acts as a pro-inflammatory cytokine during the initial 
stage of inflammation (Heinrich et al., 1990). Additionally, pro-inflammatory IL-6 can be 
secreted as an adipokine by adipose tissue (Lutosławska, 2012) whereas IL-6 with anti-
inflammatory properties is produced by skeletal muscle as a myokine (Muñoz-Cánoves et 
al., 2013). 
 
Previously in literature, IL-6 had been termed with diverse names as the molecule has 
pleiotropic effects throughout the body, influencing various cell types and bodily systems, 
with each name reflecting the effect of the molecule (Simpson et al., 1997). IL-6 was termed 
interferon (IFN)-β2 due to the molecules IFN antiviral activity (Weissenbach et al., 1980). 
Additionally, the molecule was also named B-cell stimulatory factor 2 (BSF-2) as the 
molecule has the ability to induce the process of differentiation of activated B cells into 
antibody (Ab)-producing cells (Hirano et al., 1986). Furthermore, IL-6 was termed 
hybridoma growth factor (HGF) based on the ability to enhance the growth of fusion cells 
between plasma cells and myeloma cells (Van Damme et al., 1988, Simpson et al., 1997). 
Importantly for this study, however, is the term hepatocyte-stimulating factor (HSF) given 
by Gauldie et al. (1987) based on IL-6’s ability to induce acute phase protein synthesis 
from hepatocytes. Due to the wide array of effects, it is evident that IL-6 plays a vital role 
in host defence mechanisms such as haematopoiesis, the immune response as well as in 
the acute-phase reaction. 
 
In line with this molecule’s functional pleiotropy, IL-6 has been implicated in the pathology 
of various diseases with T2DM being no different as elevated circulating IL-6 being present 
in this condition (Akbari and Hassan-Zadeh, 2018, Pickup et al., 2000). Although some 
debate in literature exists, it is believed that IL-6 alters insulin signalling via decreasing IRS-
1 protein expression, as well as required insulin-stimulated tyrosine phosphorylation and 
finally reduction in insulin-stimulated glucose transport (Rotter et al., 2003, Kristiansen and 
Mandrup-Poulsen, 2005). Furthermore, IL-6 is associated with the increased β-cell 
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apoptosis causing reduced β-cell mass and eventually insulin deficiency (Kamimura et al., 
2003). 
Interleukin 8: 
 
Interleukin-8 (IL-8), otherwise known as chemokine (C-X-C motif) ligand 8 (CXCL8), is a 
small chemoattractant protein, 72 amino acids peptides in length (Remick, 2005). Majority 
of all nucleated cells are potential sources of IL-8 however, the primary cellular sources of 
circulating IL-8 are monocytes and macrophages which secrete IL-8 in response to any 
antigens present and bound to the cells toll-like receptors (Standiford et al., 1990, Waugh 
and Wilson, 2008). IL-8 is an essential cytokine in the early phases of acute inflammation 
as it is produced in the initial phases of the inflammatory response. In contrast to most 
other cytokines, IL-8 remains active for a prolonged period post inflammation ensuring 
effective clearance of debris/bacteria at the site of interest (Vogiatzi et al., 2009).  
 
IL-8s primary role is as a neutrophil chemotactic factor whereby monocytes and 
neutrophils, cells of the acute inflammatory response, are recruited and attracted to the site 
of injury/infection/inflammation (Vogiatzi et al., 2009). This cellular recruitment transpires 
via the chemotactic gradient development, which ultimately causes the monocytes and 
neutrophils to travel towards the area of increased chemokine (IL-8) concentration ensuring 
the correct cells are recruited to the site of inflammation as well as ensuring these cells 
remain in the affected area (Gimbrone et al., 1989). In addition to this cellular recruitment, 
IL-8 is essential in the activation and promotion of phagocytotic processes of monocytes 
and neutrophils (Standiford et al., 1990). 
 
The Cimini et al. (2017) study showed that individuals presenting with T2DM have 
significantly elevated circulating IL-8 levels in comparison to that of healthy age matched 
controls. This elevated IL-8 levels further exacerbate muscle glucose uptake via the 
reduction in GLUT4 translocation which may also lead to sustained bouts of 
hyperglycaemia (Amir Levy et al., 2015). Further research into the impact of IL-8 in T2DM 
is limited. 
 
TNF- α: 
 
Tumor Necrosis Factor-α (TNF- α) is a pleiotropic cytokine with a wide array of effects 
throughout the body. In addition to being an adipokine secreted by adipose tissue, TNF- α 
is also produced by various cells in the body with monocytic cells, including macrophages, 
microglia, Langerhans cells, astroglia and Kupffer cells generally being the primary 
synthesizers of this cytokine (Pfeffer et al., 1993, Flynn et al., 1995). The TNF-α gene has 
been found to be present as a single copy gene found on human chromosome 6 with the 
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gene consisting of three introns and four exons (Spriggs et al., 1992). This Human TNF-α 
protein is then expressed as a 27-kDa (233 amino acid) protein which is proteolytically 
cleaved to form a mature and active 17-kDa (157 amino acid) soluble TNF-α (sTNF-α) 
molecule (Black et al., 1997, Parameswaran and Patial, 2010). 
 
When stimulated to be released in response to trauma, infection, or when exposed to 
bacterial-derived LPS (Feldmann et al., 1994), TNF-α acts via binding to two 
transmembrane receptors: TNF receptor1 (TNFR1), (also referred to as p55 or p60), 
constitutively expressed in the majority of mammalian tissues; and TNF receptor 2 
(TNFR2), (also referred to as p75 or p80), a more highly regulated receptor typically only 
found in the cells of the immune system (Banner et al., 1993).  The literature on the effects 
of sTNF-α binding to TNFR2 is limited, with the majority of TNF-α inflammatory effects 
being attributed to TNFR1 receptor binding (Parameswaran and Patial, 2010). 
 
The binding of TNF-α to the extracellular domain of TNFR1, causes the receptor to undergo 
a change in conformation resulting in the release of the inhibitory protein, silencer of death 
domains (SODD), which ultimately allows for the adapter protein TNF receptor-associated 
death domain (TRADD) to bind to the death domain of the receptor (Hsu et al., 1995). The 
TRADD binding induces the following three pathways:- Activation of NF-κB where free 
NFκB subunits bound to IκBα translocates to the nucleus and induces gene transcription 
of proteins such as anti-apoptotic factors, proteins involved in cell survival and proliferation, 
as well as the induction of proteins and cytokines involved in the inflammatory response 
(Vallabhapurapu and Karin, 2009). Activation of the MAPK pathways ends in an activated 
c-Jun N-terminal kinases (JNK) being translocated to the nucleus whereby genes involved 
in cell proliferation, differentiation and pro-apoptotic in nature are transcribed (Micheau and 
Tschopp, 2003, Rousseau et al., 2008). Finally although a minor role, the binding causes 
the induction of death signalling, whereby TRADD binds to Fas-associated protein with 
death domain (FADD) which in turn recruits procaspase 8 which is then cleaved leading to 
apoptosis (Gaur and Aggarwal, 2003). 
 
Further functions of TNF-α also include being a potent chemoattractant molecule for 
neutrophils, causing neutrophil migration to areas of injury/infection (Smart and Casale, 
1994) as well as promoting the expression of adhesion molecules, such as Intercellular 
Adhesion Molecule 1 (ICAM-1) and Vascular Cell Adhesion Protein 1 (VCAM-1) on 
endothelial cells (Mattila et al., 1992). Additionally, TNF-α activates macrophages and 
enhances phagocytic processes (Parameswaran and Patial, 2010). Importantly for this 
study, TNF-α is also a potent inducer of the liver to secrete and produce acute phase 
proteins (Thorn et al., 2004). 
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In T2DM, circulating TNF-α levels have been seen to be dysregulated with the Swaroop et 
al. (2012) study showing significantly elevated TNF-α levels in the disease. As previously 
discussed, this cytokine is associated with the aetiology of T2DM as it disrupts insulin 
signalling as well as influencing glucose metabolism (Aguirre et al., 2000, Zou and Shao, 
2008). 
 
MCP-1: 
 
Monocyte Chemoattractant Protein 1 (MCP-1), also known as chemokine (C-C motif) 
ligand 2 (CCL2), is a small protein 76 amino acids in length and 13 kDa in size located on 
chromosome 17 (Deshmane et al., 2009). It is primarily secreted by adipose tissue, 
macrophages, monocytes, Kupffer cells and dendritic cells generally in response to the 
presence of oxidative stress, circulating cytokines, or growth factors (Beall et al., 1996). 
 
MCP-1s main function is to act as a chemoattractant thus regulating the recruitment, 
migration as well as the infiltration of monocytes, natural killer (NK) cells, and memory T 
lymphocytes to the site of inflammation (Panee, 2012). 
 
In literature, MCP-1 is strongly associated with obesity as the circulating plasma levels of 
MCP-1 are significantly elevated in obesity, with the degree of obesity directly correlating 
with the degree of cytokine elevation (Catalan et al., 2007, Harman-Boehm et al., 2007, 
Cox et al., 2011). The elevated MCP-1 levels induce macrophage infiltration into the 
adipocytes ultimately leading in crown structure formations and mass pro-inflammatory 
cytokine release. This is possibly one of the key role players in the chronic low-grade 
inflammation associated with obesity (Kanda et al., 2006). 
 
MCP-1 is also strongly linked with T2DM, with significantly elevated MCP-1 levels being 
observed in various T2DM studies (Simeoni et al., 2004, Blaha et al., 2006, Kanda et al., 
2006). Literature suggests that MCP-1 contributes to T2DM via various pathways including 
contributing to the “Inflammation Theory”, previously discussed; through macrophage 
infiltration and crown structure cytokine signalling (Chacon et al., 2007); the induction of 
amylin secretion which causes increased circulating amylin levels (which disguises the 
actual physiological circulating glucose levels) leading to improper insulin secretion and 
hence insulin resistance (Cai et al., 2011);  MCP-1 causes ERK1/2 activation in skeletal 
muscle resulting in impaired insulin signalling as well as reducing the glucose uptake by 
myocytes through reduced GLUT-4 translocation via the NF-κB pathway. 
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MIP-1β: 
 
Macrophage inflammatory protein-1 (MIP-1), occurs in two different isoforms, MIP-1α and 
MIP-1β which are also commonly referred to in the literature as CC Motif Chemokine 
Ligand 3 (CCL3) and CCL4, respectively, and are located on chromosome 17 (Wolpe et 
al., 1988). Both MIP-1 isoforms are chemokines and act as strong chemotactic cytokines 
and are secreted by various cell types such as macrophages, dendritic cells, and 
lymphocytes (Maurer and von Stebut, 2004).  
 
MIP-1β when secreted, functions to activate human granulocytes leading to acute 
neutrophilic inflammation, as well as inducing the synthesis and release of various pro-
inflammatory cytokines such as TNF-α, IL-1 and IL-6 from macrophages (Maurer and von 
Stebut, 2004). MIP-1β also acts to maintain tissue homeostasis. 
 
Research with regards to MIP-1β in T2DM is limited but it is thought that the chemotactic 
cytokine may indirectly facilitate β-cell death through the recruitment of macrophages 
(Benoist and Mathis, 1997). 
 
sP-Selectin: 
 
P-Selectin, otherwise referred to as CD62P, is a member of the selectin family of cell 
adhesion molecules, is 50 kb in size and contains 17 exons in humans and is mapped on 
chromosome 1 (Nicaud et al., 1998).  P-selectin is found in platelets and endothelial cells 
where the adhesion molecule is stored in α-granules and Weibel-Palade bodies 
respectively (Woltmann et al., 2000). The P-Selectin is then translocated to the cell 
membrane of endothelial cells and platelets in response to the presence of pro-
inflammatory cytokines, such as IL-4, as well as the presence of thrombin (Wasiluk, 2004, 
Kamath et al., 2002). 
 
This externalised P-Selectin then plays a pivotal role in haemostasis as it mediates the 
adhesion of activated platelets to neutrophils and ultimately activating the innate immune 
response (Ebeid et al., 2014). Furthermore, the P-Selectin induces platelet-to-platelet 
binding and aggregation further ensuring haemostasis in the presence of inflammation. 
 
Additionally, P-Selectin can be secreted into circulation, with this now being termed soluble 
P-Selectin (sP-selectin), as a part of platelet-derived microparticles or as free spliced 
versions of the protein. This sP-Selectin plays a key role in immune system-mediated 
inflammation as it promotes leukocyte migration, the adherence of leukocytes to activated 
platelets and endothelium as well as the production and release of key cytokines and 
growth factors at the site of injury (Ebeid et al., 2014). 
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sP-Selectin has been shown to be significantly elevated in T2DM (Gokulakrishnan et al., 
2006, Woollard et al., 2014); however the role of sP-Selectin the pathogenesis of T2DM 
isn’t yet fully elucidated. 
 
ICAM-1: 
 
Intercellular Adhesion Molecule 1 (ICAM-1), which is also referred to as Cluster of 
Differentiation 54(CD54), is a protein encoded by the ICAM1 gene which encodes for a 
glycoprotein located on the cell surface of endothelial cells as well as cells of the immune 
system, such as leukocytes (Katz et al., 1985, Hubbard and Rothlein, 2000). These cells 
continuously present with ICAM-1 at low levels on their cell membranes, however, when 
stimulated via TNF-α (Fingar et al., 1997, Javaid et al., 2003), IL-1β, Lipopolysaccharide 
(LPS) (Myers et al., 1992) and the presence of reactive oxygen species (ROS) (Chiu et al., 
1997), ICAM-1 concentrations greatly increase. 
 
The increased presence of ICAM-1 on the cell membranes of endothelial cells, as well as 
lymphocytes and monocytes, causes increased binding to leukocytes as ICAM-1 acts as a 
ligand LFA-1, an integrin, found on the cell membrane of these leukocytes (Rothlein et al., 
1986). This cell to cell binding of endothelial cells and leukocytes then causes the 
leukocytes to transmigrate into tissues of inflammation or damage (Yang et al., 2005). In 
addition to the cell to cell binding, ICAM-1 has been observed to have signal-transducing 
functions which is associated with pro-inflammatory pathways, further shifting the cytokine 
profile towards a proinflammatory state (Etienne-Manneville et al., 1999). 
 
ICAM-1 levels have been found to be significantly elevated in T2DM (Karimi et al., 2018) 
however the impact ICAM-1 has on the disease isn’t fully elucidated. Elevated ICAM-1 may 
be as a result of elevated TNF-α and IL-1β found in T2DM, however the increased ICAM-
1 may influence T2DM pathogenesis via the binding of monocytes/leukocytes to activated 
vascular endothelium preceding macrophage and foam cell development (Price and 
Loscalzo, 1999), This is a crucial event potentially resulting in T2DM. 
 
VCAM-1: 
 
Vascular Cell Adhesion Molecule 1 (VCAM-1), otherwise known as cluster of differentiation 
106 (CD106), is a 90-kDa glycoprotein encoded by the VCAM1 gene  (Osborn et al., 1989). 
VCAM-1 expression, like ICAM-1, is activated and expressed on the cell membrane of 
endothelial cells (Rice and Bevilacqua, 1989) in the presence of various pro-inflammatory 
cytokines such as TNF-α as well as the presence of ROS (Cook-Mills et al., 2011). 
Additionally, under conditions of extensive inflammation, VCAM-1 can also be expressed 
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on the surface of various other cells types, which includes macrophages, myoblasts, 
dendritic cells, oocytes, bone marrow fibroblasts as well as Kupffer cells (Sharma et al., 
2017). 
 
When stimulated by pro-inflammatory cytokines, various ligands bind to the externalised 
VCAM-1 causing leukocyte to endothelial cell binding which starts a cascade effect which 
concludes in VCAM-1–dependent leukocyte trans-endothelial migration (Wittchen, 2009). 
 
In T2DM, literature shows that VCAM-1 is significantly elevated in T2DM (Liu et al., 2015, 
Braatvedt et al., 2001) and may be one of the leading causes of the abnormal endothelial 
function and activation observed in T2DM (De Vriese et al., 2000, Devaraj and Jialal, 2000). 
 
2.4 T2DM and the Acute Phase Response 
 
The acute phase response (APR) is a further process chronically activated in T2DM (Festa 
et al., 2002). The APR is a prominent systemic reaction that occurs in humans in response 
to any local or systemic disturbances in the body’s homeostasis, which can be caused by 
tissue injury, infection, trauma, or in the case of T2DM, chronic low-grade systemic 
inflammation (Gruys et al., 2005).  
 
Circulating TNF-α and IL-1β, mainly stimulate the resident Kupffer cells in the liver to begin 
producing and secreting IL-6, which acts as the main mediator for mass hepatocytic 
secretion of acute phase proteins (APPs), proteins of the APR (Jain et al., 2011).  
 
APPs are a class of proteins whose circulating levels are significantly altered in response 
to inflammation. The circulating protein levels can be increased, with these proteins being 
referred to as positive APP, or decreased, with these proteins being referred to as negative 
APP (Jain et al., 2011). These proteins have a wide variety of functions, however the end 
goal of the APR and the APP is to re-establish homeostasis while promoting system healing 
(Cray et al., 2009).  Table 2.1 below gives a list of all the positive and negative APPs.  
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Table 2.1. Table displaying the acute phase proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Of these APP, fibrinogen, prothrombin, factor VIII, von Willebrand factor and Plasminogen 
Activator Inhibitor-1, are important as they are all proteins involved in coagulation and 
fibrinolysis (Heinrich et al., 1995). Furthermore, the Horadagoda et al. (1999) study claims 
that the two most important APPs are C-reactive protein (CRP) and Serum Amyloid A 
(SAA). 
 
CRP: 
 
C-Reactive Protein is a protein that is 224 amino acids in length with a molecular mass of 
25,106 Da and its gene mapped onto chromosome 1 (Thompson et al., 1999). CRP is a 
member of the pentraxin family which are pattern recognition proteins that play an integral 
role in the innate immune system (Bray et al., 2016). When secreted from the liver, in 
response to IL-6, CRP forms an annular pentameric protein shape which then circulates 
throughout the body in blood plasma (Pepys and Hirschfield, 2003). 
 
CRP was first discovered by Tillett and Francis (1930) whose study initially hypothesised 
that CRP was a pathogenic secretion as it was significantly elevated in various illnesses, 
including cancer. This notion was disproved however when CRP was discovered to be 
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hepatically synthesised. CRP was later named after the molecules’ capacity to precipitate 
the somatic C-polysaccharide of Streptococcus pneumoniae (Pepys and Hirschfield, 2003) 
with the molecule becoming the first acute-phase protein to be described as a highly 
sensitive systemic marker for inflammation and tissue damage (Pepys and Baltz, 1983). 
 
When secreted, CRP acts by binding to the phosphocholine found on the surface of 
necrotic and apoptotic cells as well as on some bacteria (Gershov et al., 2000, Xia and 
Samols, 1997). The binding then allows for the activation of the complement system, thus 
enhancing and promoting phagocytosis by macrophages via opsonin-mediated 
phagocytosis (Bray et al., 2016). 
 
CRP levels have great clinical significance as the APP has been commonly used as a 
diagnostic marker for disease and systemic inflammation (Allin and Nordestgaard, 2011, 
Ligtenberg et al., 1991, Pradhan et al., 2016, Vadakayil et al., 2015). CRP levels in healthy 
individuals vary, with concentrations ranging between 0.8 mg/L to 3.0 mg/L, and sometimes 
circulating at up to 10 mg/L (Volanakis, 2001). Importantly, these circulating levels can 
increase up to 1000 times during disease or inflammation (Pradhan et al., 2016), which 
can then be clinically measured using methods such as ELISA kits, immunoturbidimetry, 
rapid immunodiffusion and nephelometry. The sensitivity of CRP in response to trauma 
and inflammation makes this APP an effective and accurate marker for determining 
disease progress as well as the effectiveness of treatments. 
 
Wang et al. (2013), among various others, showed that in T2DM, CRP levels are 
significantly elevated and can act as a strong biomarker for T2DM disease progression and 
management. 
 
SAA: 
 
Serum Amyloid A (SAA) is a generic term for a highly conserved family of acute-phase 
apolipoproteins synthesised by the liver (Eklund et al., 2012, Ye and Sun, 2015). The 
human SAA gene codes for a 122 amino acid polypeptide, which contains an 18 amino 
acid N-terminal signal sequence. Humans have four SAA genes; saa1 and saa2 which 
encode for acute-phase isoforms of SAA, saa3 which is an apparent pseudogene, and 
finally saa4 which encodes for a constitutively expressed isoform (Frame and Gursky, 
2016, de Beer et al., 1995).  
 
The SAA molecules can be divided into two groups, firstly, the acute phase SAAs that 
associate with HDL during inflammation and secondly, the constitutive SAAs, mouse SAA5 
and human SAA4 (de Beer et al., 1995). Human apo-SAA is a 104 amino acid polypeptide 
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that circulates in plasma bound to high-density lipoprotein-3 (HDL3) (Cabana et al., 1999). 
However, SAA has an important effect on HDL structure and function during inflammation, 
as the majority of SAA is an apolipoprotein of high-density lipoprotein HDL (Kisilevsky and 
Manley, 2012, Hua et al., 2009).  During acute inflammation, SAA secreted from the liver 
displaces apolipoprotein A-I bound to HDL, with each HDL particle being able to bind and 
carry several copies of SAA (Jayaraman et al., 2015), thus becoming the major 
apolipoprotein of circulating HDL3 (Eklund et al., 2012).  Acute-phase SAA also modifies 
the biological effects of HDL-C in several conditions (Zewinger et al., 2015). For the current 
study, we will focus on the acute-phase SAA as our molecule of choice. 
 
Circulating SAA has various functions including influencing cholesterol and lipid 
metabolism (Faty et al., 2012), induction of mast cell adhesion to the extracellular matrix 
(Nicholson-Weller et al., 1985), recruitment and adhesion of T cells (Xu et al., 1995), 
inducing the migration, tissue infiltration and adhesion of monocytes and 
polymorphonuclear leukocytes (Badolato, 1994) as well as the induction  of various pro-
inflammatory cytokines (Eklund et al., 2012). 
 
Importantly, depending on the extent of inflammation, it has been seen that SAA may 
increase up to 1000-fold, compared to those in the non-inflammatory state (Eklund et al., 
2012). Consequently, SAA is a well-established (and potent) biomarker for infection and 
sepsis (Malle and De Beer, 1996, Bozinovski et al., 2008, Cicarelli et al., 2008). 
Furthermore, increased SAA is also an important plasma biomarker for predicting future 
cardiovascular events and is associated with an increase in thrombotic risk (Delanghe et 
al., 2002, Johnson et al., 2004) as it is an active participant in the early atherogenic process 
(Getz et al., 2016). Furthermore, SAA’s presence is associated with the pathogenesis of 
chronic inflammatory diseases, such as T2DM as well as atherosclerosis (Eklund et al., 
2012, Thompson et al., 2015). The table below displays relative circulating SAA levels in 
various diseases. 
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Table 2.2: Literature review of the observed concentration of SAA during various diseases. 
Serum SAA concentrations (μg·mL-1) References 
The median of SAA concentration in patients with non-neoplastic 
lesions: 6.02 μg·mL-1 
(Ren et al., 
2014) 
The median of SAA concentration in patients with cervical 
intraepithelial neoplasia: 10.98 μg·mL-1 
The median of SAA concentration in patients with cervical 
carcinoma: 23.7 μg·mL-1 
SAA concentration in acute coronary syndrome associated with 
cardiovascular risk factors: 57.1 (50.0–64.3) mg·L-1  
(Zewinger 
et al., 2015) 
SAA concentration in diabetes associated with cardiovascular 
risk factors 36.1 (28.7–43.4) mg·L-1  
SAA4 levels in controls: 55 ± 13 mg·mL-1 (Malle and 
De Beer, 
1996) SAA levels during pneumonia: 10 to 1700 mg·mL
-1 
SAA4 levels during pneumonia: 6 to 150 mg·mL-1 
80 μg·mL-1 SAA showed regulation of apoptotic targets and a 
dose-dependent reduction in cell viability, with 69% cell viability 
observed following exposure to 80 μg/mL of SAA for 24 hours to 
cells in culture. 
(Tan et al., 
2014) 
 
 
2.5 SAA and the circulating inflammagen LPS 
 
Bacterial lipopolysaccharides (LPS), also referred to as lipoglycans or endotoxins, are 
essential components of the outer membrane of gram-negative bacteria and is associated 
with low-grade chronic inflammation (Guo et al., 2013). LPS’s role is to provide structural 
integrity to the bacteria as well as providing the cell membrane protection from various 
types of chemical attack (Zhang et al., 2013). This LPS however is shed in to the 
haematological system via dormant bacteria (Hurley, 1995, Pretorius et al., 2018a) or is 
constantly entering the blood system, possibly as a result of the individual suffering from 
leaky gut or gut dysbiosis (Sylvia and Demas, 2018, Saltzman et al., 2018). 
 
When LPS is found in the haematological system, it acts as a classical endotoxin, thus 
binding to the CD14/TLR4/MD2 receptor complexes found on various cell types including; 
macrophages, monocytes, dendritic cells and B cells, inducing the promotion and secretion 
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of pro-inflammatory cytokines and nitric oxide (Frost et al., 2002, Qureshi et al., 2012). 
Furthermore, LPS induces the production of superoxide, making it a major source of 
reactive oxygen species (Hsu and Wen, 2002, Park et al., 2015). 
 
Crucial for this study is that a link exists between LPS and SAA with the Migita et al. (2004) 
study showing that LPS signalling induces hepatocytes to secrete SAA. Furthermore, the 
Fukushima et al. (2000) study showed that SAA is an essential molecule in LPS induced 
inflammation. Importantly, both SAA (Eklund et al., 2012, Marzi et al., 2013) and LPS 
(Creely et al., 2007, Khondkaryan et al., 2018) are upregulated in T2DM. 
 
2.6 T2DM, Inflammation and the Coagulation System 
 
Coagulation is the physiological process which regulates haemostasis, the arrest of 
bleeding, and is the initial stage of wound healing (Palta et al., 2014). The haemostasis 
process can be subdivided into two phases, namely primary and secondary haemostasis.  
 
Primary haemostasis occurs due to complex interactions between platelets, damaged 
vessel walls as well as various local adhesive proteins which ultimately leads to the 
formation of a ‘platelet plug’ at the site of damage (Lasne et al., 2006). Platelets are “egg” 
shaped, anucleate cellular fragments derived from megakaryocytes (Palta et al., 2014) 
whose membrane consists of various integrins,  glycoproteins, phospholipids and various 
receptors (Ibrahim and Kleiman, 2017). The various receptors, including fibrinogen, 
vitronectin, collagen, fibronectin and laminin receptors in circulating platelets are kept at a 
“resting” low-affinity state, however, these receptor types are transformed into high affinity 
“activated” receptors when the platelets are activated when bound and adhered to the 
damaged endothelial collagen in a von Willebrand Factor (vWF) mediated binding process 
(Heemskerk et al., 2002, Li et al., 2010). This conversion from low affinity to high 
conversion receptor types is called “inside-out signalling” (Li et al., 2010) and mediates 
platelet adhesion and aggregation at the site of endothelial damage as well as initiating 
thrombus formation (Coller and Shattil, 2008). For this aggregation and adhesion to occur, 
the newly activated platelets begin to undergo conformational changes whereby the 
platelets form cytoplasmic foot-like extensions referred to as pseudopodia, causing the 
membrane to flatten in an attempt to cover an increased surface area at the site of damage 
(Pretorius et al., 2018c). The binding of external fibrinogen to the fibrinogen integrin 
receptors on the activated platelets then initiates a series of intracellular events, referred 
to as “outside-in signalling”, which results in platelets undergoing a degranulation process, 
whereby cytokines and proteins such as  P-selectin, fibronectin, fibrinogen, factor VIII, 
factor V, platelet factor IV, platelet-derived growth factor, calcium and thromboxane A2 
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(TxA2) are secreted into circulation (Heemskerk et al., 2002, Li et al., 2010). The TxA2 
secreted then acts as a stimulus inducing further circulating platelets to bind and enlarge 
the platelet aggregation leading to the formation of the platelet plug, which temporarily 
seals the damaged site (Palta et al., 2014). 
  
The secondary phase of haemostasis consists of the coagulation cascade which 
culminates in the formation of insoluble, crosslinked fibrin meshes at that site of 
injury/damage (Gale, 2011). Although named the secondary phase, fibrin formation has 
been seen to occur simultaneously to the process of platelet aggregation (Falati et al., 
2002). As seen in figure 2.1 below, the coagulation cascade can be activated through two 
pathways; the intrinsic and extrinsic pathway. 
 
The intrinsic/contact activation pathway is initiated when there is damage to blood vessels 
and endothelial collagen is exposed which causes the activation of clotting factor XII, 
otherwise referred to as Hageman Factor (Renne et al., 2012). This activation begins a 
cascade effect resulting in the calcium-dependent activation of clotting factor X (Smith et 
al., 2015). The activation of factor X is where the intrinsic and extrinsic pathways merge 
with the extrinsic/tissue factor pathway being initiated through tissue damage which 
initiates the secretion of tissue thromboplastin (Scarpati et al., 1987). This thromboplastin, 
known as clotting factor III, then activates factor X in a process mediated by calcium. 
 
Activated factor X then converts circulating prothrombin, secreted by the liver, into thrombin 
which is an essential molecule in the conversion of fibrinogen into insoluble thin “spaghetti 
like” fibrin fibres (Palta et al., 2014, Pretorius et al., 2017c). Thrombin also crucially 
activates factor XIII, a molecule which functions to covalently crosslink fibrin polymers vital 
in the formation of a stable secondary haemostatic plug (Ariens et al., 2002). Additionally, 
thrombin induces the production of the molecule thrombin activatable fibrinolysis inhibitor 
(TAFI) which protects the newly formed fibrin clot from undergoing fibrinolysis (Bombeli 
and Spahn, 2004). 
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Figure 2.1. Summary of the coagulation cascade occurring during secondary haemostasis adopted 
from Sherwood (2013). 
 
Literature shows that inflammation and the clotting cascade are two systems that are 
heavily linked to one another with excessive cross talk occurring between the two systems 
(Esmon, 2005, Foley and Conway, 2016, Levi and van der Poll, 2010). Kell and Pretorius 
(2015) went on to show that there are two key hallmark features in the blood of systemic 
inflammation; hypercoagulation, the increased propensity for clot formation and 
hypofibrinolysis, the increased resistance of the formed clots to undergo lysis. 
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Table 2.3. Table displaying selected biomarkers and how they influence the haematological system and 
cause hypercoagulation and hypofibrinolysis. Adapted from Randeria et al. (2019) (unpublished). 
 
 
 
 
 
Name of 
Biomarker 
Role on the Haematological System and Coagulation 
IL-1β - Induction in the synthesis of clotting factor VII within monocytes (Carlsen et al., 1988) 
- Enhancing expression of tissue factor and activity from endothelial cells and 
monocytes (Herbert et al., 1992) 
- Induction of IL-6 signalling pathways producing pro-coagulant fibrinogen synthesis 
(Yang et al., 2013) 
- Induction of platelet hyperactivation (Bester and Pretorius, 2016) 
- Downregulation of thrombomodulin thus reducing anticoagulation capacity (Bester 
and Pretorius, 2016) 
IL-6 - Promotion of fibrinogen gene expression through stat3 phosphorylation (Duan et al., 
2010) 
- Induction of platelet hyperactivation (Bester and Pretorius, 2016) 
- Upregulating circulating tissue factor levels (Bester and Pretorius, 2016) 
IL-8 - Induction of platelet hyperactivation and spreading (Bester and Pretorius, 2016) 
- Induction of eryptosis in erythrocytes (Bester and Pretorius, 2016) 
- Induction of aberrant fibrin formation (Bester et al., 2018) 
- Reduction is fibrin lysis rate (Bester et al., 2018) 
TNF-α - Induction of platelet clumping and activation and the development of spontaneous 
plasma protein dense matted deposits (Page et al., 2018) 
- Induction of plasminogen activator inhibitor (PAI-1) thus reducing fibrinolytic capacity 
(Pandey et al., 2005) 
- Downregulates thrombomodulin thus increasing levels of tissue factor (Scarpati and 
Sadler, 1989) 
MCP-1 - Induction of tissue factor expression in monocytes (Ernofsson and Siegbahn, 1996) 
sP-
Selectin 
 
- Induces the expression of tissue factor by monocytes (Celi et al., 1994) 
- Induces platelet to platelet binding and platelet aggregation (Pretorius et al., 2018c) 
- Facilitates leukocytes recruitment thus promoting leukocyte-mediated fibrin 
deposition (Palabrica et al., 1992) 
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In addition to the biomarkers/inflammatory cytokines inducing haematological and 
hypercoagulation effects, the APP’s induced in inflammation also influence these systems. 
Positive APPs includes fibrinogen, factor VIII, von Willebrand factor, PAI-1 and 
thrombopoietin all of which induce a pro-coagulant state leading to hypercoagulation 
(Patalakh and Kudinov, 2008, Spencer et al., 2007). Furthermore, the negative APPs 
include antithrombin and thrombomodulin which further contributes to the pro-coagulant 
state found in inflammation. 
 
With an increased circulating fibrinogen level complemented with increased clotting factor 
availability, all diseases associated with chronic low-grade inflammation should be 
accompanied by a state of hypercoagulation. This notion has widely studied in literature 
with the hypercoagulable and hypofibrinolysis state being observed in Alzheimer’s disease 
(Gupta and Pansari, 2003, Gupta et al., 2005), cancer (Francis et al., 1994, Rickles and 
Falanga, 2001, Rickles and Levine, 2001, Viale, 2005), cardiovascular disease (Borissoff 
et al., 2011, Tantry et al., 2010), sepsis (Hesselvik et al., 1989, Bernard et al., 2001), 
Parkinson’s disease (Pretorius et al., 2014), Human Immunodeficiency Virus (Shen and 
Frenkel, 2004) and T2DM (Alzahrani and Ajjan, 2010, Beijers et al., 2012, Carr, 2001, 
Pretorius et al., 2015, Pretorius et al., 2017b, Pretorius et al., 2018c, Thor et al., 2002). 
Furthermore, literature has begun to recognise that inflammatory diseases are associated 
with, and may be exacerbated and even caused by, amyloid fibril formation (Chiti and 
Dobson, 2006, Herczenik and Gebbink, 2008, Rambaran and Serpell, 2008). These 
amyloid fibrils are defined as: “a protein that is deposited as insoluble fibrils, mainly in the 
extracellular spaces of organs and tissues as a result of sequential changes in protein 
folding that result in a condition known as amyloidosis” (Sipe et al., 2014). 
 
The interest in this notion, with respect to haematology, was peaked when Pretorius et al. 
(2016a) proved that the insoluble fibrin(ogen) formed during thrombosis could be amyloid 
in nature in the presence substoichiometric levels of bacterial lipopolysaccharide. Fibrin is 
normally produced via the thrombin-mediated polymerisation of the circulating protein 
fibrinogen, whereby two fibrinopeptides are removed, which allows the fibrinogen to self-
assemble via a ‘knobs and holes’ mechanism into thin spaghetti-like fibres (Weisel, 2005, 
Wolberg, 2007). The fibrin in the Pretorius et al. (2016a) study however was misfolded and 
amyloidogenic, with the fibrin’s normally alpha-helical dominate structures being changed 
into fibrin with regions rich in β-sheets. Pretorius et al. (2017b) went on further to show, 
using novel amyloid-selective fluorescent stains, that the fibrin clots formed in T2DM were 
also amyloidogenic in nature. This finding potentially implicated a bacterial component in 
the development of T2DM as the T2DM fibrin exhibited similar structural alterations to that 
of the fibrin incubated with LPS. 
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More recently, Page et al. (2019) implicated SAA in the amyloidogenic fibrin(ogen). The 
study was based on the premise that elevated plasma concentrations of SAA would result 
in aggregation as amyloid in β-sheet fibrillar deposits and that SAA and fibrinogen could 
be co-deposited in the amyloid fibrils. The study displayed that the incubation of ex vivo 
SAA in platelet-poor plasma induced a significant amyloid signal, using amyloid-selective 
fluorescent stains, of fibrin clots thus proving that SAA does, in fact, induce β-sheet rich 
fibrin fibrils. This study demonstrations that LPS may not be the only molecule causing the 
aberrant amyloidogenic fibrin clots that occur in T2DM; however, the amyloidogenic 
potential of SAA in the context of T2DM needs further investigating. 
 
2.8 Mopping agents 
 
When it was determined that fibrin(ogen) exposed to LPS  could in fact be amyloid in 
nature, Pretorius et al. (2017a) showed that Lipopolysaccharide binding protein (LBP) has 
the potential to significantly reduce, but not completely remove, the amyloid signal found 
in T2DM.  Furthermore, Pretorius et al. (2018b) went on to show that ex vivo LBP incubation 
into PPP from Parkinson’s disease patients also showed a significant reduction in fibrin clot 
amyloid signal. These two studies demonstrate that the addition of “mopping agents” can 
remove and reduce the majority of the LPS derived amyloid signal. Despite this, residual 
amyloid signal always remained thus hinting towards the requirement of multiple mopping 
agents to completely abolish amyloid structure formation. 
 
Since Page et al. (2019) discover of SAA amyloidogenic effects on fibrin(ogen) clots, one 
could hypothesize that an effective SAA mopping agent in combination with LBP will 
potentially remove amyloid signal completely. An effective mopping agent would be a 
molecule that effectively binds to SAA and thus completely sequesters its effects on 
fibrinogen. One potential SAA mopping agent is high-density lipoprotein (HDL), a molecule 
SAA naturally binds with, causing the displacement of Apolipoprotein A-I (de Beer et al., 
2010). Furthermore, a single HDL molecule can bind multiple SAA molecules (Frame and 
Gursky, 2016), thus potentially making it an extremely effective mopping agent. 
Additionally, the use of SAA anti-bodies may be a further potential avenue for the binding 
and mopping of SAA’s effects as these antibodies would bind with extreme specificity thus 
targeting and inhibiting SAA’s effects. 
 
In theory, the use of SAA mopping agents is a viable option to inhibit the molecules’ 
amyloidogenic effects on fibrin(ogen), however further in-depth experimental research is 
required to determine the viability of this notion. 
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2.9 Concluding Remarks  
 
In this literature review, T2DM was shown to be associated with chronic low-grade 
inflammation, an altered inflammatory profile and a chronically activated APR system. This 
altered profile was shown to influence the haematological system as it influences not only 
blood components but the coagulation cascade causing a hypercoagulable state. This 
inflammatory state and the presence of SAA is associated with aberrant fibrin clot formation 
whereby the fibrin becomes amyloidogenic in nature with a change in protein structure from 
alpha-helical dominated fibres becoming beta-rich sheet dominant in structure. The use of 
LBP as a mopping agent was shown to reverse this state with SAA mopping agents 
potentially being able to facilitate LBP in completely abolishing amyloid signal in fibrin. The 
figure below displays a general overview of the literature review. 
 
Figure 2.2. Summary diagram of topics covered in the above literature review. 
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3. Study Design 
 
3.1 Ethical clearance and considerations 
 
Ethical clearance for the study was obtained from the Health Research Ethics Committee 
I (HREC I) from University of Stellenbosch (South Africa) (HREC Project Reference #6399 
S18/02/036: G Thomson) (Appendix A). Prior to any involvement in the study both the 
“seemingly healthy” control (without T2DM), as well as clinically diagnosed T2DM 
participants, received an in-depth verbal as well as written explanations of the study before 
participants signed a compulsory consent form (Appendix B) (available on request) 
acknowledging their participation within the study. All participant information, both T2DM 
and controls, was kept strictly confidential with the principle investigator being the only 
person able to access the data. Importantly all investigators involved in the study were 
certified in Good Clinical Practice. Strict ethical codes of conduct were followed during 
blood sample collection, in addition to all methodologies being carried out in line with the 
relevant guidelines of the ethics committee (HREC Reference # S18/02/036: G Thomson). 
Lastly the Declaration of Helsinki was strictly adhered to by all investigators. 
 
3.2 Study Layout 
 
A cross-sectional study design was performed in collaboration with Dr Laubscher from the 
Mediclinic in Stellenbosch who provided the whole blood (WB) from T2DM study 
participants. WB samples from healthy control participants were collected at the 
Department of Physiological Sciences at the University of Stellenbosch by the qualified 
on-site phlebotomist after a consensual recruitment process. 
 
3.3 Study Population  
 
The current study was performed at Department of Physiological Sciences at the 
University of Stellenbosch in the Clinical Hemorheology and Coagulation research group. 
The study involved the recruitment of n=75 (n=36 “seemingly healthy” control participants, 
n=39 T2DM participants) male and females over the age of 30 (Table below). Individuals 
were classified as “seemingly healthy” controls if they were observably healthy and not 
presenting any symptoms of disease, not on chronic medication, having no prior history of 
thrombotic disease or inflammatory conditions as well as being non-smokers. 
Furthermore, females were excluded upon the use of contraception in addition to being 
pregnant and/or lactating at the time of sample collection. Participants unable to provide 
written consent were further excluded from the study. Finally, post sample collection 
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exclusion occurred, such as samples CC28 and CW19 from table 3.2 below, if the 
“seemingly healthy” control individuals’ displayed Pathcare inflammatory profile tests 
values above the recommended/healthy baseline values. 
 
Inclusion criteria for T2DM patients included both male and female participants that had 
been diagnosed with T2DM at least 3 months prior to the study. The Diabetic individuals 
were diagnosed according to the Society for Endocrinology, Metabolism and Diabetes of 
South Africa (SEMSDA) guidelines which follow the American Diabetes Association (ADA) 
criteria to define T2DM. The Diabetics individuals also did not present with any signs of 
infection at the time of sample collection. Congruent with healthy controls, smokers and 
pregnant and/or lactating women were excluded at the time of sample collection.  
 
To limit and exclude any possible confounding factors, study participants from both the 
control and diabetic groups were only included if they did not have HIV, tuberculosis or 
any malignancies.  
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Table 3.1. Table displaying the demographics of the study participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Bar graph representing the most commonly prescribed chronic medication used by the 
T2DM study participants at the time of involvement of the study.  
 
Healthy Individuals 
(n =36) 
Diabetic Individuals 
(n=39) 
P-
values 
Gender 
Male (n=16) 
Female (n=20) 
Male (n=20) 
Female (n=19) 
 
Age 
(years) 
58.11 ± 1.86 64.44 ± 2.00  
HbA1c 
(%) 
5.25 ± 0.09 8.96 ± 0.45 <0.0001 
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Table 3.2. Table displaying the Pathcare analysis of control participants of the study, with HbA1c having reference range of between  3,9-6,1%, Total Cholesterol  
(S-cholesterol) < 5,0 mmol/L , Total HDL (S-HDL) >1,2 mmol/L, Total LDL (S-LDL) <3,0 mmol/L, Total Triglycerides (S-Triglycerides) < 1,70 mmol/L, Total Non-
HDL cholesterol (S- Non-HDL) <3,8 mmol/L, Cholesterol:HDL ratio <4,0 and finally ultrasensitive CRP levels <1mg/L
Stellenbosch University https://scholar.sun.ac.za
 
 
32 
 
3.4 Blood Sample Collection 
 
Blood samples were obtained from fasted participants, for accurate HbA1c and cholesterol 
analyses, via venepuncture of the median cubital vein with whole blood samples being 
collected in one 4.0 mL ethylenediaminetetra-acetic acid (EDTA) tube (BD Vacutainer®, 
367861), two 4.5 mL sodium citrate (3.2%) tubes (BD Vacutainer®, 369714) and one 8.5 
mL serum separating tube (SST) (BD Vacutainer®, 367958). 
 
3.5 Blood Sample Preparation  
 
Samples collected in the SST and EDTA tubes of the healthy control participants were 
sent to Pathcare Laboratory, Stellenbosch for the analyses (Table below) of blood 
parameters such as ultra-sensitive C-Reactive Protein (us-CRP), glycosylated 
haemoglobin (HbA1C) and cholesterol levels. Whole blood samples collected in the two 
Citrate tubes were inverted approximately 10 times directly after blood sample collection 
before being left for a minimum of 30 minutes at room (±22 °C) temperature to allow the 
sodium citrate to remove all available calcium from the whole blood, inhibiting thrombosis. 
The whole blood was then used to make whole blood smears for electron microscopy as 
well as being used in the thromboelastography (TEG) methodology. Residual whole blood 
in the Citrate tubes were centrifuged at 3000 g for 15 minutes at room temperature (±22 
°C) to separate blood components whereby the platelet poor plasma (PPP) was collected 
using a Pasteur pipette and aliquoted into labelled 2 mL Eppendorf tubes before being 
stored at -80°C. 
 
3.6 Blood Sample Exposure 
 
In addition to analysis of naïve whole blood, samples were exposed to various molecules 
and mopping agents. The SAA and HDL used in this study was obtained as a donation 
from Prof F de Beer, Kentucky University USA. 
 
To determine the appropriate concentration for the test, previous literature was assessed, 
and it showed that physiological SAA levels vary (refer to table 2.2 in chapter 2). Following 
on from Page et al. (2019), it was determined that a final concentration of 30 µg.ml-1 SAA 
would be used in the study as it represents a relevant physiological level of the molecule. 
Previous studies performed by Pretorius et al., 2017 observed a significant reduction in 
amyloid signal when using 2 ng.L-1, despite this, not all signal was abolished therefore the 
LPS-binding protein concentration used in this study will be at 5 ng.L-1. After consulting 
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the literature of relevant physiological levels, a final exposure concentration of 30 µg.ml-1 
HDL will be used in the study.  
 
Once added, all molecules and mopping agents were given a minimum of 10 minutes to 
allow for reaction and binding prior to analysis/addition of further added molecules. 
Importantly, SAA was always incubated in the sample last allowing for the mopping agents 
to have the greatest chance to bind and mop the SAA effects. The following table describes 
the exposure details used within the study. 
 
Table 3.3. Table displaying the varying sample exposure schedules used during the study. 
 
 
 
 
 
 
 
 
 
 
 
3.7 Statistical Analysis  
 
All statistical analyses were performed using GraphPad/Prism version 7.04 (GraphPad 
Software, San Diego, USA). Each parameter was analyzed using descriptive statistics for 
the entire study, whereby normality was assessed using the Shapiro-Wilks normality test. 
On the premise that data was distributed normally, paired as well as unpaired T-tests were 
performed to determine between group analysis. When the standard deviations of the 
groups compared differed, a Welch’s correction was implemented. This parametric data is 
expressed as the mean ± standard error of the mean (SEM). In contrast, non-parametric 
data was analyzed using the Mann–Whitney test to report differences between appropriate 
groups. This non-parametric data is expressed as box and whisker plots. Where 
necessary, outliers were identified and removed using the ROUT method whereby the Q 
CONTROL STUDY   EXPERIMENTAL STUDY  
NAIVE CONTROL BLOOD  Naïve T2DM blood  
+ SAA ( 30  µg.m L - 1 )  +  HDL ( 30 µg.m L - 1 )  
+ HDL ( 30  µg.m L - 1 )  +  LBP ( 5 ng. L - 1  )  
+ LBP ( 5 ng .L - 1  )  +  HDL (  30 µg.m  L - 1 )  +  LBP(  5 ng.  L - 1  )  
+ HDL ( 30  µg.m L - 1 ) + SAA (  30  µg.m   L - 1 )    
+ HDL ( 30  µg.m L - 1 ) + LBP ( 5 ng..  L - 1  )    
+ LBP ( 5 ng. L - 1  )  + SAA ( 30  µg.m L - 1 )    
+ HDL ( 30  µg.m L - 1 ) + LBP ( 5 ng. L - 1  ) + SAA ( 30  
µg.m L - 1 )  
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value was set at 1%. Additionally, mixed model ANOVA was implemented where relevant 
with a Dunnett’s multiple comparisons pos hoc test being used to determine where 
differences between groups exist. Finally, statistical significance was accepted at p < 0.05. 
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4. Control vs Type II Diabetes Mellitus 
 
4.1 Introduction 
 
In this chapter, blood from individuals presenting with Type II Diabetes Mellitus was 
compared to that of age matched control samples. The comparison was completed using 
both quantitative and morphological markers. The quantitative markers include biomarker 
analyses via the analysis of cytokine profiles using a 20-plex inflammatory cytokine assay 
as well as a V-plex inflammatory and tissue injury assay. In addition to this, the efficiency 
of coagulation was analysed using thromboelastography. The morphological markers 
include the use of scanning electron microscopy for the analysis of whole blood and fibrin 
clots, as well as the use of confocal microscopy to analyse amyloid signal in fibrin clots. 
This chapter was aimed at determining if an altered circulating cytokine profile is present 
in T2DM, whether elevated levels of SAA occurs in the disease, and how this altered 
cytokine and APP profile may affect the haematological system. 
 
The following paragraphs give brief introductions to each technique as well as the 
application in which they can be used in this study. 
 
Biomarker analysis: 
 
As the prevalence of non-communicable diseases increase, the need for new 
methodologies and markers for the early diagnosis, management of disease progression 
and pharmacological responses to therapeutic intervention are essential in managing this 
ever-growing socio- and economic burden. Consequently, biomarkers have become a 
growing field of interest in the science field. Biological markers otherwise referred to as 
biomarkers was defined by Hulka and Wilcosky (1988) as biochemical, cellular or 
molecular alterations that are measurable in biological media such as human cells, fluids 
or tissues. This definition however has extended with time to include any biological 
characteristics which can be measured and evaluated as an indicator of any normal or 
abnormal physiological processes which includes pathogenic and therapeutic responses 
(Naylor, 2003).  
 
Two main categories for biomarkers exist, namely: biomarkers of exposure and 
biomarkers of disease (Mayeux, 2004, Perera and Weinstein, 2000). Biomarkers of 
exposure are used when an individual is suspected of suffering from a condition or disease 
due to exposure to a toxin, these biomarkers when analysed would allow for risk prediction 
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of the exposure/disease. An example of this would be the analysis of hair or nail samples 
to determine lead levels in an individual who had previously been exposed to lead which 
would allow a practitioner to determine the patients risk of lead poisoning. 
 
Of more interest to this study is that of the biomarkers of disease, as these markers allow 
for disease prognosis, the early screening of diseases as well as the development of 
diagnostic tests (Selleck et al., 2017, Burke, 2016). The latter two allow for the detection 
of the disease at a more primitive stage in the disease progression which would generally 
allow for a more favourable treatment outcome. Biomarkers for various diseases exist in 
literature already such as the BRCA1/2 gene for breast and ovarian cancer and HbA1c 
levels in Diabetes Mellitus (Savolainen et al., 2017, Selleck et al., 2017). 
 
Biomarkers can vary greatly as the markers can be genomic markers, whereby DNA 
analysis occurs with specific respect to single nuclear polymorphisms (SNPs), 
transcriptomic biomarkers which uses the analysis of RNA profiles, protein markers which 
analyses protein expression levels and finally metabolic markers analysing metabolites 
and intermediates of metabolism (Hwang et al., 2018). Due to the varying types of 
biomarkers, methods to quantify the marker levels vary greatly.   
 
For this study, the biomarkers analysed was that of protein expression. Consequently, a 
multiplex cytokine analyses were performed using the Invitrogen’s Inflammation 20-Plex 
Human ProcartaPlex™ Panel (catalogue number:  EPX200-12185-901) to determine the 
cytokine profile (TNF- alpha; IL-1 beta; IL-6; IL-8; MCP-1; MIP-1 beta and sP-Selectin) of 
both the control as well as T2DM participants. Additionally, a Meso Scale Discovery V-
Plex Vascular Injury Panel 2 Human Kit (catalogue number: K15198D-1) was performed 
to determine levels of biomarkers linked with inflammation and tissue damage (CRP, SAA, 
ICAM-1 and VCAM-1). 
 
Thromboelastography (TEG): 
 
Previous research has shown that a hallmark of systemic inflammation is that of a 
hypercoagulable and hypofibrinolytic state in the coagulation system (Kell and Pretorius, 
2015) which one would be able to determine using Thromboelastography, otherwise 
known as TEG. TEG is a point of care method commonly used in hospitals for surgeries, 
anaesthesiology and the assessment of coagulopathies (Bose and Hravnak, 2015, Howley 
et al., 2018, Pretorius et al., 2017c). TEG assesses the coagulation system and determines 
overall haematological health by providing information about various clotting parameters, 
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kinetics as well as providing an indication of the fibrin clot structure and strength (Nielsen 
et al., 2007a, Nielsen et al., 2007b, Swanepoel et al., 2015, Kell and Pretorius, 2015, 
Pretorius et al., 2017c). These clotting parameters can then be used as a measure of the 
degree of pathology of the coagulation status.  
 
Table 4.1.1 Table defining the 7 viscoelastic parameters generated by the TEG. Table adopted from 
(Pretorius et al., 2017c)  
 
 
 
  
 
PARMETERS 
 
EXPLANATION 
R value: reaction time 
measured in minutes 
Time of latency from start of test to initial fibrin formation (amplitude 
of 2 mm); i.e. initiation time 
K: kinetics measured in 
minutes 
Time taken to achieve a certain level of clot strength (amplitude of 
20 mm); i.e. amplification 
Α (Alpha) Angle: slope 
between the traces 
represented by R and K. 
Angle is measured in 
degrees 
The angle measures the speed at which fibrin build up and cross 
linking takes place, hence assesses the rate of clot formation; i.e. 
thrombin burst 
MA: Maximal Amplitude 
measured in mm 
Maximum strength/stiffness of clot. Reflects the ultimate strength of 
the fibrin clot, i.e. overall stability of the clot 
Maximum rate of 
thrombus generation 
(MRTG) measured in 
Dyn.cm-2.s-1 
The maximum velocity of clot growth observed or maximum rate of 
thrombus generation using G, where G is the elastic modulus 
strength of the thrombus in dynes per cm-2 
Time to maximum rate 
of thrombus generation 
(TMRTG) measured in 
minutes 
The time interval observed before the maximum speed of the clot 
growth 
Total thrombus 
generation (TTG) 
measured in Dyn.cm-2  
The clot strength: the amount of total resistance (to movement of 
the cup and pin) generated during clot formation. This is the total 
area under the velocity curve during clot growth, representing the 
amount of clot strength generated during clot growth 
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Table 4.1.2 Table showing how the viscoelastic parameters will change in hypercoagulable and 
hypocoagulable states. Table adopted from (Pretorius et al., 2017c) . 
 
 
 
The TEG machine uses cup and pin mechanics where citrated WB or PPP is added into 
the cup before CaCl2 is added to initiate fibrin clot formation. The cup is then rotated at a 
4° 45′ arc, six times a minute, at a temperature of 37 °C mimicking the conditions of slow 
blood flow in the venous circulation. A stationary pin attached to a torsion wire is then 
inserted into the cup, whereby newly formed fibrin attaches. This binding causes the pin 
to begin to drag forming mechanical energy, in the form of resistance, on the wire which is 
then transduced into an electrical current which is analysed by the computer software. The 
computer then uses various algorithms to produce a split symmetrical reaction curve. The 
magnitude of this curve is then directly proportional to the strength of the clot formed over 
time (Bose and Hravnak, 2015). Table 4.1.1 and table 4.1.2 above describes the 
parameters generated using the TEG in addition to how these parameters will alter when 
in a hypercoagulable or hypocoagulable state.  
  
HYPERCOAGULABLE 
 
 
HYPOCOAGULABLE 
R  
min 

  
Clot forms faster  Clot forms slower 
     
K  
min 
 Clot reaches a set (20 
mm) strength quicker 
 
 
Clot reaches a set (20 mm) 
strength slower 
Α  
Alpha 
 
 
 
An increased thrombin 
burst resulting in more 
cross-linking of fibrin 
fibres 
 A decreased thrombin burst 
resulting in less cross-linking of 
fibrin fibres 
MA  
mm 
 
 
Increased platelet* 
and/or fibrin(ogen) 
interaction resulting in a 
denser clot that is more 
rigid 
 Decreased platelet* and/or 
fibrin(ogen) interaction resulting in 
a denser clot that is less rigid 
MRTG** 
Dyn.cm-2.s-
1 
 
 
 
Increased clot growth  
 
 Decreased clot growth 
TMRTG** 
min 
 Decreased time from 
clot initiation to 
maximum clot formation  
 
 
Increased time from clot initiation 
to maximum clot formation 
TTG** 
Dyn.cm-2 
 Increased clot strength   Decreased clot strength 
*platelet activity only in whole blood not PPP 
**In whole blood MRTG, TMRTG and TTG focuses on the fibrin in the sample 
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Scanning Electron Microscopy: 
 
A dysregulated circulating cytokine profile has previously been shown to cause changes 
in the haematological system (Esmon, 2005, Choi et al., 2006, Conway, 2012, Kell and 
Pretorius, 2015, Swanepoel et al., 2015) as these cytokines are constantly interacting with 
erythrocytes, platelets, circulating fibrin(ogen) as well as other various proteins involved in 
coagulation. These alterations may be seen indirectly via a hypercoagulable state 
observed using TEG, however direct imaging of the alterations is an extremely valuable 
way in determining the exact impact that the dysregulated cytokine profile is having on the 
haematological system. 
 
The method of Scanning Electron Microscopy (SEM) allows scientist the ability to analyse 
whole blood smears for red blood cell morphology, platelet morphology and activation 
status as well as factors such as erythrocyte to erythrocyte interaction, agglutination status 
and finally platelet to platelet interaction (Pretorius et al., 2018c, Pretorius et al., 2017c). 
Additionally, SEM allows for the analysis of fibrin fibre morphology when imaging fibrin 
clots. Using this method, one can directly visualise fibrin fibre diameter as well as the 
presence of any aberrant fibrin fibres. Additionally, visualisation of proteins interacting with 
the fibrin clots formed is another power of this technique (Pretorius et al., 2016a). 
 
Confocal Microscopy: 
 
Confocal microscopy is an optical imaging technique which uses fluorescent markers to 
image samples. Confocal microscopy is a technique that allows for great optical resolution 
as the microscope captures multiple two-dimensional images at various depths of the 
sample before images are analysed and processed to form three-dimensional structures 
(Paddock, 2000). Furthermore, confocal microscopy provides micrographs with excellent 
contrast as the technique makes use of a spatial pinhole which blocks out any background 
light (Paddock, 2000, Thorn, 2016). 
 
Due to the increased resolution and contrast, confocal microscopy is a technique widely 
used throughout science, however in the context of this study, the technique was used to 
determine amyloid signal found in fibrin clots. Various fluorescent markers and dyes exist 
but for this study we made use of three; Thioflavin T (ThT), Amytracker™ 480 and 
Amytracker™ 680. 
 
ThT is a classic amyloid fluorescent marker (Biancalana and Koide, 2010, Biancalana et 
al., 2009, Naiki et al., 1989) as it has a strong affinity and thus binds to β-sheet rich areas 
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which are found in high concentrations within amyloid regions. The ThT emits a strong 
fluorescent signal at 482 nm when excited at 450 nm (Naiki et al., 1989). Additionally, two 
proven fluorescent amyloidogenic markers (Magnusson et al., 2014), which are 
luminescent conjugated oligothiophenes (LCOs) dyes, marketed as Amytracker™ 480 and 
Amytracker™ 680, were used for this study.  Previous work completed by the Clinical 
Hemorheology and Coagulation research group has proven the viability of these two 
Amytrackers in the context of amyloid formation in fibrin clots (Pretorius et al., 2017b, 
Pretorius et al., 2018a) as it was shown that the two markers stain for similar but somewhat 
different areas in comparison to that of ThT. 
 
4.2 Materials and Methods 
 
Material and methods for quantitative markers: 
 
20-Plex Cytokine Analysis: 
 
On the morning of the experiment, stored PPP from the -80°C freezer was thawed on ice 
while the Invitrogen’s Inflammation 20-Plex Human ProcartaPlex™ Panel (catalogue 
number:  EPX200-12185-901) was removed from the 4 °C refrigerator before both were 
allowed to reach room temperature (±22 °C). PPP samples were then vortexed before 25 
µL of each sample was added to 25 µL of internal controls. This sample dilution was then 
pipetted into each sample’s designated well in the 96-well plate, which had been pre-
incubated with washed magnetic beads. The plate was then sealed before being placed 
on a shaking bed for 90 minutes at 500 rpm at room temperature (±22 °C). 25 µL of the 
1X detection antibody was then added to each well before again being sealed and 
incubated on the plate shaker for 30 minutes at room temperature (±22 °C). The detection 
antibody was then removed, and each well was washed twice using the 1X wash buffer 
for 30 seconds per wash.  50 µL of the Streptavidin, R-Phycoerythrin Conjugate (SAPE) 
solution was added per well before the plate was covered and allowed to incubate of the 
plate shaker for 30 minutes at 500 rpm. Following this, a series of two wash steps occurred 
before 120 µL of the reading buffer was added to each well. The 96-well plate was covered 
and placed on the plate shaker to incubate for 5 minutes while being agitated at 500 rpm. 
The plate was then analysed using a Bio-Plex® 200 (BioRad Luminex) system with all 
inflammatory markers being presented in pg.mL-1. The protocol was completed and 
analysed at the Department of Biochemistry at Tygerberg Medical campus.  
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V-Plex Cytokine Analysis: 
 
Similar to that of the Inflammation 20-Plex Human ProcartaPlex™ Panel, on the day of the 
experiment, stored control and T2DM PPP were removed from the -80 °C and thawed on 
ice before being allowed to reach room temperature (±22 °C). While PPP samples thawed, 
the Meso Scale Discover Vascular Injury Panel 2 (human) Kit (catalogue number: 
K15198D-1) was removed from the 4 °C refrigerator and allowed to reach room 
temperature. The 96-well plate was then washed 3 times for 30 seconds using 150 µL per 
well of the 1X wash buffer provided. 25 µL of diluted (1:1000 in diluent 101) plasma 
samples, in addition to internal controls, were then pipetted into assigned wells. The plate 
was sealed and allowed to incubate at room temperature (±22 °C) for 2 hours while on a 
plate shaker rotating at 500 rpm. The plate was washed again 3X 30 seconds using the 
wash buffer before 25 µL of a master-mix of the 4 detection antibodies (SULFO-TAG Anti-
human SAA Antibody; SULFO-TAG Anti-human CRP Antibody, SULFO-TAG Anti-human 
VCAM-1 Antibody and SULFO-TAG Anti-human ICAM-1 Antibody) was added to each 
well. The plate was sealed and covered before being incubated on the plate shaker for an 
hour at room temperature. The plates were wash a further 3 times using the 1X wash 
buffer before 150 µL of the 1X read buffer provided was added to each well before the 
plate was immediately analysed using the MSD Discovery Workbench 4 machine. Data 
received was measured in pg.mL-1 before being multiplied by 1000 to account for the 
dilution used. The values were then converted and presented in µg.mL-1. The protocol was 
completed and analysed at the Department of Biochemistry at Tygerberg Medical campus. 
 
Thromboelastography: 
 
TEG analysis was performed on naïve (untreated) control and T2DM whole blood samples 
drawn in the sodium citrate (3.2%) tubes (BD Vacutainer®, 369714). Briefly 20 mL of 0.2 
M calcium chloride (CaCl2) (Haemoneticsâ, 7003) was pipetted into a disposable TEG cup 
(Haemoneticsâ, HAEM 6211) before 340 mL of the whole blood was then added to the 
cup. The calcium chloride reverses the effects of the sodium citrate thus initiating 
fibrin(ogen) clot formation which is then analysed using a Haemoscope TEG® 5000 
Haemostasis Analyser. Importantly, before each day of use, a e calibration test was 
performed on the TEG machine to ensure the two channels were in equilibrium. 
Furthermore, internal quality control checks were performed every 50 runs of the TEG to 
ensure the accuracy of the readings generated.  
Stellenbosch University https://scholar.sun.ac.za
 
 
42 
 
 
 
Materials and Methods for morphological markers: 
 
Scanning Electron Microscopy: 
 
For whole blood analysis: 10 μL of WB from control and T2DM patients was used to 
prepare scanning electron microscopy smears. The sample was pipetted onto the 10 mm 
round glass slide before gently being smeared over the surface of the slide, this was left 
for ± 3 minutes to allow for attachment to the slide. The slides were then transferred into a 
24 well plate before being washed with 1X Gibco™ PBS (phosphate-buffered saline), pH 
7.4 (ThermoFisher Scientific, 11594516). The smears were fixed with 4% 
paraformaldehyde in PBS for at least 30 min, before three 1X PBS washes. The samples 
were then fixed with 1% osmium tetroxide (Sigma-Aldrich, 75632) in double distilled H2O 
for an additional 30 min in the fume hood. Following this, the samples were washed three 
times in 1X PBS before a series of ethanol dehydration steps were performed in which 
samples were washed in increasing concentrations (30%, 50%, 70%, 90% and 100%) of 
ethanol for 3 minutes in each concentration with the 100% step being repeated three times 
to ensure full dehydration. A final dehydration step was then performed in 99.9% 
hexamethyldisilazane ReagentPlus® (Sigma-Aldrich, 379212) for 30 minutes in the fume 
hood before being left to air dry in a fume hood overnight (± 16 h). The dried samples were 
then mounted on glass microscope slides which had been covered in double-sided carbon 
tape. These slides were then carbon coated immediately before scanning electron 
microscopy ultrastructural analyses of the whole blood could be performed. All imaging 
was performed on the Zeiss MERLIN™ field emission scanning microscope located in the 
Central Analytical Facility (CAF) Electron Microbeam Unit, Stellenbosch University. All 
micrographs were captured using the high resolution InLens capabilities at 1 kV. 
 
For fibrin analysis: 10 µL of Platelet Poor Plasma from control and T2DM participants were 
pipetted onto the 10 mm round glass slide before 5 µL of Thrombostin Human Thrombin 
(lot number: 090118T) was added and mixed into the sample. The glass slides were 
immediately transferred to the 24 well plate before the rest of the protocol was followed as 
stated above.  
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Confocal Microscopy: 
 
On the day of imaging, stored PPP of control as well as T2DM samples were removed 
from the -80 °C freezer before being allowed to thaw and reach room temperature (±22 
°C). 95 µL of each sample was pipetted into a labelled 2 mL Eppendorf tube before 2 µL 
of each Amytracker™ (final exposure concentration of 0.1 µL stock solution into 100 µL 
PPP of Amytracker™ 480 and 680) and 1 µL of ThT (final concentration 5 µM) was added 
and allowed to incubate in the dark for at least 30 minutes. Once incubation had finished, 
10 µL of the PPP + fluorescent marker mixture was pipetted onto a labelled microscope 
slide before 5 µL of thrombin (provided by the South African National Blood Service) was 
added and mixed into the PPP to form an extensive fibrin network. This was left for 30 
seconds before a cover slip was placed onto of the newly formed fibrin clot before the 
samples were imaged immediately using a Zeiss LSM 780 with ELYRA PS1 confocal 
microscope with a Plan-Apochromat 63x/1.4 Oil DIC objective at the CAF Fluorescent 
Microscope Unit in Stellenbosch University campus. For this study; Amytracker™ 480 was 
excited using the 405 nm excitation laser whereby the emission was measured at 478–
539 nm; Amytracker™ 680 was excited using the 561 nm excitation laser before the 
emission was measured at 597–695 nm; and ThT was excited using the 488 nm excitation 
laser whereas the emission was measured at 508–570 nm. Images were then processed 
using Image J where images were split into each channel before histograms were created 
with the mean fluorescent intensity and standard deviation being recorded. The coefficient 
of variation was then calculated using the following formula: 𝐶𝑉 =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐷𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
. 
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4.3 Results 
 
4.3.1 20-Plex Cytokine Analysis 
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Figure 4.3.1.  Graphs of measured circulating inflammatory markers: A- Interleukin-1 Beta (IL-1β), 
B -Interleukin-6 (IL-6), C - Interleukin-8 (IL-8), D - Tumor Necrosis Factor alpha (TNF-α), E - 
Monocyte Chemoattractant Protein-1 (MCP-1), F - Macrophage Inflammatory Protein-1β (MIP-1β) 
and G - soluble-P selectin measured using Invitrogen’s Inflammation 20-Plex Human ProcartaPlex 
Pane in 25μL of platelet-poor plasma of control (n=24) and Type II Diabetic Mellitus (n=25) 
individuals. Parametric data (Graph D) is expressed as mean ± SEM where as non-parametric data 
(Graphs A, B, C, E, F and G) is presented as box and whisker plots. Significance is set as *p < 
0.05; ***p < 0.001 and ****p < 0.0001. All data is presented in pg. mL-1. Values in controls that were 
lower than detectable ranges were allocated 0.001.  
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Upon analysis of the Inflammation 20-Plex Human ProcartaPlex™ Panel it is evident that 
the T2DM population used within this study had an altered inflammatory cytokine profile 
producing a pro-inflammatory state. This was observed with significant differences in all 
seven of the relevant parameters used in this study. With regards to IL-1β, graph A in 
figure 4.2.1, the T2DM groups average circulating levels were ±3 times greater than that 
of the age matched control group (p < 0.0001). Additionally, the circulating IL-6 levels, 
graph B, were significantly different (p < 0.0001) between the two groups with the mean 
value of the T2DM group being around 573 pg.mL-1 in comparison to that of the control 
groups mean value of 10.26 pg.mL-1. Significant differences (p = 0.0013) were also 
observed in circulating IL-8 levels, graph C, with a ± 6 times greater mean circulating 
cytokine difference between the two groups. Following the trend of the interleukin pro-
inflammatory cytokines, TNF-α, graph D, was also significantly elevated (p = 0.0019) in 
T2DM with a near double average circulating protein concentration found in T2DM 
participants in comparison to the control group. 
 
Furthermore, the chemoattractant cytokines MCP-1 and MIP-1β, graphs E and F, were 
both found to be significantly altered (p = 0.0025 and p = 0.0137) in the T2DM population 
with a ± 1.8 and ± 2.1 times elevated circulating levels respectively compared to the control 
group. The final biomarker assessed in this assay was soluble P-selectin, graph G, which 
was also significantly dysregulated (p = 0.021) in the diabetic participants with these 
individuals having on average ± 3000 pg.mL-1 more circulating P- selectin molecules in 
circulation at any given time. 
 
4.3.2 V-Plex Cytokine Analysis  
 
When analysing figure 4.3.2 below, it is evident that the T2DM population used in this 
study has a dysregulated inflammatory profile. Graph A shows that in Diabetes Mellitus, 
individuals have a significantly elevated (p < 0.0001) circulating CRP level with the median 
and mean circulating concentrations being ± 4 and ± 12 times greater respectively than 
that of the age-matched control group. Furthermore, graph B shows a similar significant 
difference (p < 0.0001) between the two groups with regards to circulating Serum Amyloid 
A levels. Analysis shows that the diabetic group’s average circulating concentrations were 
10-fold higher than that of the control group. When analysing the adhesion markers, I-
CAM-1 and VCAM-1 (graph C and D), both parameters proved to be significantly elevated 
in the diabetic group (p = 0.009 and p = 0.023 respectively). When assessing the figure as 
a whole, a distinct difference in the inflammatory profile between the two populations is 
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clear to see with all the T2DM individuals having a significant pro-inflammatory cytokine 
profile. 
Figure 4.3.2.  Graphs of measured circulating inflammatory and tissue damage markers: A- C-
Reactive Protein (CRP), B – Serum Amyloid A (SAA), C – soluble Intercellular Adhesion Molecule 
1 (ICAM-1) and D – soluble Vascular Cell Adhesion protein 1 (VCAM-1) measured using the Meso 
Scale Discover Vascular Injury Panel 2 (human) Kit using platelet-poor plasma of control (n=36) 
and Type II Diabetic Mellitus (n=39) individuals. Parametric data (Graph D) is expressed as mean 
± SEM where as non-parametric data (Graphs A, B and C) is presented as box and whisker plots. 
Significance is set as *p < 0.05; ***p < 0.001 and ****p < 0.0001. All data is presented in µg.mL-1.   
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4.3.3 Cytokine Correlations 
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Figure 4.3.3. Correlations between Serum Amyloid A and the other 10 cytokine markers 
assessed. Parametric data (image D and J) were assessed using the Pearson’s correlation test 
and is presented with a linear regression line. Non-parametric data was assessed using the 
Spearman’s correlation test. The number of data points assessed per correlation ranged from n 
=23 to n=33.   
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Assessing the relationship between all ten measured inflammatory cytokines and Serum 
Amyloid A, one can start by inferring that the data indicates no correlation exists between 
SAA and IL-8 (r = 0.211; p =0.335), TNF-alpha (R2 =0.010; p = 0.588), sP-Selectin (r = 
0.072; p = 0.692) as well as VCAM-1 (R2 = 0.181; p = 0.313) depicted in images C, D, G 
and J respectively. 
 
In contrast however, trends towards moderately significant correlations were noted 
between SAA and MCP-1 (r = 0.315; p = 0.075), MIP-1β (r = 0.343; p = 0.051) and ICAM-
1 (r = 0.308; p = 0.082) images E, F and I respectively. Furthermore, a significant (p = 
0.044) moderate association between SAA and IL-6 (r = 0.377) was observed. Finally, a 
strong and very strong significant correlation was detected between SAA and IL-1β (r = 
0.435; p = 0.012) as well as CRP (r = 0.834; p < 0.0001). These results indicate SAA is 
linked and associated to various inflammatory cytokines which are associated with diverse 
roles in the human body.  
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4.3.4 Thromboelastography 
 
 
Figure 4.3.4. Bar graphs representing the 7 viscoelastic parameters assessing efficiency of 
coagulation in whole blood of Control (n= 16) and T2DM (n= 15) participants. Data was generated 
using the Haemoscope TEG® 5000 Haemostasis Analyser. Parametric data (Graph A, C and G) is 
represented as mean ± SEM and analysed using Welsh’s corrected T-test where as non-parametric 
data (Graph B, D, E and F) is expressed as box and whisker plots and were analysed using a Mann-
Whitney test. Significance is set as *p < 0.05; ***p < 0.001 and ****p < 0.0001.  
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The results displayed in figure 4.3.4 show a significant difference in all seven viscoelastic 
parameters assessed by the TEG. For the three parameters measured in time, reaction 
rate (Graph A), clot kinetics (Graph B) and the time to maximum rate of thrombus 
generation (Graph F), the T2DM participants had significantly reduced (p = 0.0044; p = 
0.0002 and p = 0.0024 respectively) time periods. This difference indicates that fibrin clots 
of T2DM participants are being initiated and are reaching their maximal speed of thrombus 
generation at a more rapid rate than that of age matched controls. Moreover, the maximum 
rate of thrombus generation (Graph E) is significantly higher (p = 0.0003) in the T2DM 
population. 
 
When assessing the stability and strength of the thrombus formed, again significant 
differences exist between the two groups assessed in the study. The alpha angle (Graph 
C), which represents the speed at which fibrin build up and cross linking takes place is 
significantly greater (p <0.0001) in the T2DM individuals in comparison to that of control 
group. Furthermore, the maximal amplitude (Graph D) is elevated (p = 0.0082) in the T2DM 
group indicating that the clot formed was significantly stiffer and more stable. This was 
further confirmed in graph G whereby the total clot strength was significantly stronger (p = 
0.0140) in the T2DM individuals. 
 
When comparing the results presented in figure 4.3.4 with traits defined in table 4.1.2 
above, the changes displayed in all 7 of the viscoelastic parameters fall in the line with 
changes that occur in the hypercoagulable state; thus individuals with T2DM have an 
increased propensity for thrombus generation. 
 
4.3.5 Scanning Electron Microscopy 
 
Qualitative analysis of the representative whole blood smear SEM images depicted in 
figure 4.3.5.1 below, reveal morphological alterations in the T2DM individuals (represented 
in C, D, E and F) in comparison to that of age matched control individuals. These images 
were selected as they are representative images that reflect a trend observed in majority 
of both control and T2DM samples imaged. In images A the erythrocytes are presenting 
with their regular biconcave shape with slight contact activation of the platelets being 
observed. This is confirmed in image B where similarly the erythrocyte is biconcave and 
the platelets attached are not overly activated. In contrast however, Images C and D show 
the eryptotic morphology of the erythrocytes in T2DM, additionally image C shows 
hyperactivation of the platelets whereas image D depicts the agglutination of erythrocytes 
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that occur in diabetic blood. Focusing on the platelets of T2DM individuals, image E shows 
platelet activation and spreading which is further shown in image F in conjunction with 
platelet aggregation and agglutination. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.5.1. Representative micrographs taken on the Zeiss MERLIN™ field emission scanning 
microscope of whole blood from Control “A and B” and Type II Diabetic “C, D, E and F” participants. 
Images were captured at various magnifications using high resolution InLens capabilities at 1 kV.
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Figure 4.3.5.2. Representative micrographs taken on the Zeiss MERLIN™ field emission scanning microscope of fibrin clots formed from control (image A and 
B) and age matched Type II Diabetes Mellitus (image C and D) platelet poor plasma. Images were captured at 5000X (image A and C) as well as 10000X 
(image B and D) using the high resolution InLens capabilities at 1 kV. 
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When qualitatively analysing fibrin clot images, figure 4.3.5.2 above, clear morphological 
alterations can be seen in the clots of the T2DM individuals (image C and D) when 
compared to that of age matched control clots (image A and B). The control fibrin clots 
have thin “spaghetti like” fibrin fibres with large open areas between the various fibrin fibres 
which can be seen in image A and B. In contrast however, in the clots formed from the 
T2DM PPP, no singular fibrin fibres can be seen, instead large dense matted amyloid fibrin 
areas are seen with little to no open areas in the clot. Furthermore, the small white spots 
seen in image D are small plasma proteins than have been trapped in the thick dense 
matted amyloid fibrin.  
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4.3.6 Confocal Microscopy 
 
Figure 4.2.6.1. Representative fibrin clots from control PPP (image A) and Type II Diabetes Mellitus 
PPP (image B). Images from channel left to right represents Amytracker 680 (red), Amytracker 480 
(blue) and Thioflavin T (green) respectively. All images were captured at 63X magnification using a 2X2 
tile scan on the Carl Zeiss LSM 780 confocal microscope. 
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Figure 4.2.6.2. Graphs displaying coefficient of variation (CV) values extrapolated using Image J 
from fibrin clot confocal micrographs of control PPP (n = 5) and Type II Diabetes Mellitus PPP (n = 
10). Parametric data (image A and C) was analysed using Welch’s corrected t test and is 
represented as the mean ± SEM whereas non-parametric data (image B) was analysed using a 
Mann-Whitney analysis and is represented as box and whisker plots. Significance is set as *p < 
0.05; ***p < 0.001 and ****p < 0.0001. 
 
Analysis of figure 4.2.6.2 above shows that a significant increase (p = 0.0002) was 
observed in the red Amytracker 680 fluorescent channel when comparing the control fibrin 
clots to that of age matched T2DM fibrin clots. The mean fluorescent intensity was ± 5 
arbitrary units (AU) greater in the T2DM fibrin clots. Furthermore, a significant increase (p 
< 0.0001) in the ThT signal was also observed with a near double in fluorescent signal 
being seen in the T2DM individuals. Finally, a trend (p = 0.0804) was observed in the 
Amytracker 480 channel when the control fibrin clots were compared to that of the age 
matched T2DM fibrin clots.  
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4.4. Discussion 
 
The initial aim of this chapter was to determine whether individuals presenting with T2DM 
do in fact have an altered cytokine profile when compared to that of healthy age matched 
control individuals. A multiplex assay was performed with the results being displayed in 
Figure 4.3.1 whereby one can see a significant increase in all the circulating pro-
inflammatory cytokines (IL-1β, IL-6, IL-8 and TNF-α) thus indicating a pro-inflammatory 
state in T2DM. This finding aligned well with literature as various studies implicate chronic 
low-grade inflammation with T2DM (Xu et al., 2003, Pickup, 2004, Pickup and Crook, 
1998). Furthermore, the specific pro-inflammatory cytokines analysed in this study: IL-1β 
(Maedler et al., 2002, Ehses et al., 2007), IL-6 (Akbari and Hassan-Zadeh, 2018, Pickup 
et al., 2000), IL-8 (Cimini et al., 2017) and TNF-α (Swaroop et al., 2012, Zou and Shao, 
2008) have been previously observed to be significantly elevated in T2DM.  
 
The multiplex assay in addition to the VPLEX assay, figure 4.3.2, further showed that the 
profile of chemokines (MCP-1 and MIP-1β) and cell adhesion molecules (sP-Selectin, 
ICAM-1 and VCAM-1) are also altered and upregulated in T2DM. Again, the results are in 
line with literature as MCP-1 (Simeoni et al., 2004, Blaha et al., 2006), MIP-1β (Maier et 
al., 2008), sP-Selectin (Gokulakrishnan et al., 2006, Pretorius et al., 2018c), ICAM-1 
(Karimi et al., 2018) and VCAM-1 (Liu et al., 2015, Braatvedt et al., 2001) have been seen 
to be altered in patients presenting with T2DM. 
 
The cytokine profile analysis shows that T2DM is indeed a condition associated with 
chronic low-grade inflammation and an altered cytokine profile. Due to the increased 
presence of these proinflammatory cytokines in T2DM, it is expected to observe increased 
circulating levels of APPs (Festa et al., 2002), a hypercoagulable and hypofibrinolytic 
coagulation state (Kell and Pretorius, 2015), altered erythrocytes and platelet morphology 
(Bester and Pretorius, 2016, Page et al., 2018) as well as amyloidogenic fibrin clot 
formation (Pretorius et al., 2016a).  
 
Following on from the first chapter aim, a VPLEX assay, displayed in figure 4.3.2, was 
performed to determine whether in fact elevated circulating levels of SAA and other APPs 
exist in T2DM. As T2DM is a condition associated with chronic inflammation, and our 
previous results proving there to be an altered cytokine profile, it is expected to see 
elevated levels of APPs such as SAA and CRP especially as it has already been observed 
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that IL-6, a potent inducer of the APR (Jain et al., 2011), is significantly upregulated. This 
proved true as both CRP and SAA, figure 4.3.2, were upregulated 12 and 10 times 
respectively. Elevated CRP levels are a common trend in inflammatory diseases, as the 
molecule is a potent biomarker for inflammation (Allin and Nordestgaard, 2011, Vadakayil 
et al., 2015). Further to this, significantly elevated CRP levels have been observed in 
various T2DM studies (Hu et al., 2004, Soinio et al., 2006, Wang et al., 2013); thus the 
results obtained from the VPLEX analysis aligns well with literature surrounding T2DM and 
the APR. In line with CRP, SAA is another APP widely researched as a biomarker for 
various inflammatory conditions (Malle and De Beer, 1996, Bozinovski et al., 2008), with 
T2DM featuring as one of these (Marzi et al., 2013, Griffiths et al., 2017). The circulating 
SAA levels observed in this study were significantly elevated in T2DM in comparison to 
healthy age matched controls. The SAA levels in this study displayed a 10-fold significant 
increase, this however doesn’t fully match literature as it has been seen that SAA can be 
upregulated up to 1000-fold (Eklund et al., 2012). 
 
In literature, IL-1β and TNF-α are major inducers of the production of the cytokine IL-6 by 
hepatic Kupffer cells which then mediates the secretion of SAA and other APPs (Jain et 
al., 2011). When correlation analyses were performed, significant correlations were 
observed SAA and IL-1β, IL-6 and CRP (figure 4.3.3). This is expected as it was previously 
stated that IL-1β and IL-6 are inducers of the secretion of APPs while CRP is an APP itself, 
therefore it is expected to be secreted at the same time as SAA. Trends towards significant 
correlations were observed between SAA and MCP-1 which may potentially be as a result 
of Kupffer cells being a source of MCP-1 (Hildebrand et al., 2006) thus when stimulated to 
secrete APPs, the activated Kupffer cells also secreted MCP-1 as a by-product of 
activation. Furthermore, a correlation trend was observed between SAA and MIP-1β, 
which may be attributed to the fact that MIP-1β binds and activates macrophages (Maurer 
and von Stebut, 2004, Hsieh et al., 2008), thus with Kupffer cells being specialised resident 
hepatic macrophages, MIP1-β may potentially bind to these cells and be an alternate 
inducer of the secretion of APPs. 
 
The fact that no correlation was observed between SAA levels and TNF-α was a surprising 
finding in this study as in literature TNF-α is commonly associated with this APR (Thorn et 
al., 2004, Jain et al., 2011). The reason for this finding is not completely understood 
however, it is hypothesised that due to TNF-α being a ligand that is able to bind to various 
cell types and having vast functions throughout the body. Consequently, the majority of 
the TNF-α in T2DM may be bound to the various cell types thus not being able to be 
effectively measured using the multiplex analysis that was performed in this study. As a 
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result, the correlation analysis for this cytokine and SAA would not give an accurate 
measurement. Additionally, it may be plausible that IL-1β is in fact a greater inducer of the 
IL-6 production and thus the APR than that of TNF-α. 
 
To evaluate the third aim of this chapter of how an altered cytokine profile can influence 
the haematological system, viscoelastic parameters of the coagulation system, visualising 
morphological changes of erythrocytes, platelets and fibrin clots as well as quantifying the 
amount of amyloid signal found in the insoluble fibrin clots were performed. When 
analysing the seven viscoelastic parameters that assesses the efficiency of coagulation, 
figure 4.3.4, the coagulation system of the T2DM group formed fibrin clots at a more rapid 
rate while the clots formed were significantly stronger and more stable. These results are 
in line with various studies performed previously (Bester et al., 2018, Kell and Pretorius, 
2015, Page et al., 2018, Pretorius and Bester, 2016, Pretorius et al., 2015, Pretorius et al., 
2017c) whereby the hallmark of inflammation is hypercoagulability. This may be one of the 
causative factors in why individuals suffering with T2DM are highly susceptible to suffering 
cardiovascular complications and strokes (Low Wang et al., 2016). 
 
Analysis of the morphology of the erythrocytes and platelets in WB of T2DM, figure 4.3.5.1, 
indicates that the altered cytokine profile induces erythrocyte eryptosis, platelet 
hyperactivation, platelet aggregation as well as agglutination. Similar results have been 
observed in literature (Pretorius et al., 2015, Pretorius et al., 2016b, Pretorius et al., 
2018c). These whole blood alterations can be attributed to elevated IL-1β, IL-6 and IL-8 
inducing platelet hyperactivation (Bester and Pretorius, 2016), TNF-α and sP-Selectin 
inducing platelet clumping and agglutination (Page et al., 2018) and IL-8 inducing eryptosis 
(Bester and Pretorius, 2016). Furthermore, the pro-inflammatory state in T2DM induces 
the formation of thick dense matted amyloid deposits in fibrin clots, figure 4.3.5.2. This is 
another phenomenon that the Clinical Hemorheology and Coagulation research group at 
Stellenbosch University has previously observed (Kell and Pretorius, 2016, Pretorius et 
al., 2016a, Pretorius et al., 2017a, Pretorius et al., 2017b, Swanepoel et al., 2015). The 
dense matted fibrin clots may be a further contributing factor in T2DM individuals increased 
susceptibility to cardiovascular diseases and complications. This phenomenon can be 
attributed to the altered cytokine profile inducing increased availability in various clotting 
factors (Carlsen et al., 1988, Bester and Pretorius, 2016, Ernofsson and Siegbahn, 1996, 
Celi et al., 1994), increased circulating levels of fibrinogen (Spencer et al., 2007) and down 
regulated levels of antithrombin and thrombomodulin (Patalakh and Kudinov, 2008). 
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Finally, the amyloid signal quantified in PPP clots, figure 4.2.6.1, was significantly 
increased in the T2DM clots compared to the control clots. This result is agreeing with 
previous literature whereby T2DM fibrin had dramatically higher amyloid signal (Pretorius 
et al., 2016a, Pretorius et al., 2017a, Pretorius et al., 2017b). It must be noted that the 
healthy control group did however have elevated amyloid signal which may be due to 
population size used in the control group being only 5 samples. Despite this, the significant 
amyloid signal using ThT and the two Amytrackers produce results that match the 
observations seen in the fibrin clot SEM analysis.  
 
Assessing this chapters results, it is evident that an altered cytokine profile exists in T2DM, 
circulating SAA levels in T2DM are significantly raised and that these two alterations 
induce a profound effect on the haematological system by inducing hypercoagulation, 
eryptosis, platelet hyperactivation and agglutination as well as amyloid fibrin clot formation.  
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5. Control Study  
 
5.1 Introduction 
 
In this chapter, all the experiments were performed on control blood and PPP. Serum 
Amyloid A was added in vitro to determine the effects of this molecule on the efficiency of 
coagulation as well as to determine if the molecule effects whole blood and fibrin 
morphology. Additionally, High Density Lipoprotein was added ex vivo as it is known that 
it binds to SAA, this chapter thus aims to determine the amyloidogenic potential of SAA 
and whether the addition of HDL may be able to negate the effects of SAA on the 
haematological system. Furthermore, LPS-binding protein was added ex vivo as we know 
LPS is associated with SAA thus potentially the binding protein may be able to “mop” the 
effects of SAA on the haematological system. 
 
5.2 Materials and Methods 
 
Material and methods for quantitative markers: 
 
Thromboelastography: 
 
The protocol followed for the TEG is identical to that described in chapter 4. The only 
alteration is that in addition to analysis of naïve whole blood, control blood was exposed 
to LPS, HDL and LBP as well as various combinations of the afore mentioned molecules. 
For a detailed description of the exposures please refer to table 3.4. 
 
Material and methods for morphological markers: 
 
Scanning Electron Microscopy  
 
Protocols for both whole blood and fibrin analysis followed was identical to that of chapter 
4. Whole blood morphology analysis was conducted on naïve control blood as well as 
blood exposed to SAA, LBP and HDL as well as the combinations discussed in table 3.4. 
Fibrin clot morphology was assessed using naïve control PPP as well as PPP incubated 
with 30 µg.mL-1 SAA. 
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Confocal Microscopy 
 
The protocol followed is identical to the protocol discussed in depth in chapter 4. Naïve 
fibrin clots as well as fibrin clots of naïve control PPP exposed to 30 µg.mL-1 SAA were 
imaged and analysed. 
 
5.3 Results 
 
5.3.1 Thromboelastography Results 
 
Table 5.3.1. Table displaying the 7 viscoelastic parameters assessing efficiency of coagulation in 
whole blood of control participants (n=14). Data was generated using the Haemoscope TEG® 5000 
Haemostasis Analyser. All samples were incubated with 30 µg.mL-1 Serum Amyloid A, 5 ng.L-1 
Lipopolysaccharide- binding protein and HDL 30 µg.mL-1 as well as varying combinations of the 
aforementioned molecules. Incubation of each molecule was 10 minutes per molecule added with 
SAA always being added last. Friedman tests and one-way ANOVAs were performed with a 
Dunnett’s Multiple comparison being used to compare the mean of each group to that of the mean 
of the naïve group. Data is presented as the mean and interquartile ranges with significance set as 
*p < 0.05; ***p < 0.001 and ****p < 0.0001.   
  
Viscoelastic Parameter 
R-Value 
(mins) 
K-
Value 
(mins) 
Alpha 
Angle 
(deg) MA (mm) 
MRTG 
(Dyn.cm
-2.s-1) 
TMRTG 
(mins) 
TTG 
(dyn.cm-2) 
T
re
a
tm
e
n
t 
re
g
im
e
 
Naïve 
7.79 
[6.95 - 
8.4] 
2.84 
[2.45 - 
3.00] 
60.71 
[59.50 - 
64.10] 
56.30 
[53.88 - 
59.53] 
4.53 
[4.03 - 
5.26] 
11.05 
[9.73 - 
12.00] 
662.00 
[584.10 - 
735.90] 
SAA 
6.97 
[6.53 - 
7.65] 
2.96 
[2.38 - 
3.43] 
61.01 
[58.48 - 
64.08] 
55.18 
[53.88 - 
59.03] 
4.36 
[3.48 - 
5.20] 
10.51 
[9.71 - 
11.00] 
625.70 
[586.80 - 
721.00] 
LBP 
7.02 
[6.25 - 
7.55] 
2.84 
[2.38 - 
3.20] 
61.80 
[59.13 - 
64.00] 
53.99 
[51.98 - 
56.50] 
4.33 
[3.74 - 
5.05] 
10.05 
[8.92 - 
11.02] 
595.30 
[544.30 - 
650.70] 
HDL 
7.63 
[6.55 - 
8.18] 
3.11 
[2.48 - 
3.80] 
59.46 
[56.05 - 
63.35] 
55.32 
[53.65 - 
58.13] 
4.24 
[3.61 - 
5.18] 
11.01 
[9.23 - 
12.96] 
628.30 
[577.20 - 
698.20] 
HDL + 
SAA 
6.56 
[5.68 - 
7.33] * 
2.79 
[2.40 - 
3.25] 
61.87 
[60.80 - 
64.73] 
55.06 
[52.93 - 
58.00] 
4.64 
[3.94 - 
5.65] 
9.64 
[8.65 - 
10.87] 
617.20 
[565.80 - 
659.80] 
HDL + 
LBP 
6.66 
[6.08 - 
7.33] 
3.04 
[2.35 - 
3.73] 
60.28 
[57.10 - 
65.28] 
54.07 
[51.70 - 
57.28] 
4.33 
[3.61 - 
5.05] 
9.97 
[8.67 - 
11.02] 
593.90 
[536.50 - 
672.60] 
LBP + 
SAA 
6.00 
[5.20 - 
7.00] *** 
2.94 
[2.38 - 
3.30] 
62.93 
[60.15 - 
66.30] 
53.36 
[49.58 - 
56.58] * 
4.43 
[3.83 - 
5.12] 
8.66 
[7.61 - 
10.10] ** 
580.80 
[487.20 - 
653.70] 
HDL + 
LBP + 
SAA 
5.87 
[4.95 - 
7.08] 
**** 
2.68 
[2.35 - 
2.93] 
64.05 
[61.28 - 
66.75] 
53.66 
[51.45 - 
56.98] * 
4.96 
[3.94 - 
5.57] 
8.61 
[7.36 - 
10.29] 
*** 
594.40 
[532.50 - 
664.40] 
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The control study was performed using control whole blood samples (n=14) collected in 
sodium citrate tubes, whereby naive samples were analysed before 7 different molecules, 
mopping agents as well as the combinations of the molecules was incubated in the sample 
prior to analysis. A summary of which can be found in table 3.4. Table 5.3.1. above shows 
that the Serum Amyloid A, High density lipoprotein and LPS -binding protein groups alone 
as well as HDL+ LBP group did not cause any significant differences in any of the seven 
viscoelastic parameters assessed in comparison to that of the control naïve group. 
 
Three of the combination groups however did produce significant changes. When HDL 
was incubated in conjunction with SAA, a significant reduction (p = 0.0208) was observed 
in the R-value hence causing the initial thrombus generation to occur at a more rapid rate. 
When LBP and SAA were incubated together, the R-value and time to maximal rate of 
thrombus generation (TMRTG) as well as the maximal amplitude (MA) were all significantly 
reduced (p = 0.0002, p = 0.0013 and p = 0.0142 respectively). This means that LBP and 
SAA together were causing the rate of thrombus generation to increase while the end clot 
formed had a reduced clot strength potentially due to decreased platelet and/or 
fibrin(ogen) interaction. Finally, the treatment group with all three molecules incubated 
together produced a similar effect to that of the LBP+SAA group where significant 
reductions (p < 0.0001, p = 0.0383 and p = 0.0008) were again observed in the R-value, 
TMRTG and MA. This again indicates that the treatments caused the rate of thrombus 
generation to increase while the end clot formed had a reduced clot strength potentially 
due to decreased platelet and/or fibrin(ogen) interaction. 
 
5.3.2 Scanning Electron Microscopy Results 
 
Qualitative analysis of the control study whole blood SEM micrographs indicates that the 
LBP alone (image C below) and the HDL+LBP combination (image E below) incubation 
were the only two treatment groups that produced no noticeable morphological change in 
comparison to that of the naïve control images. In contrast, the HDL (image B) and the 
SAA alone incubation (image D) displayed noticeable differences in the platelet 
morphology and activation status, this can be seen in both images by the widespread 
membranes of the platelets as well as the occurrence of platelet aggregation. It must be 
further noted that in the SAA alone treatment (not represented in images below), the 
presence of eryptotic erythrocytes were observed thus indicating that SAA causes 
alterations in platelet and erythrocyte morphology. The HDL + SAA incubation showed 
signs of disrupting the membrane of erythrocytes (image F) as well as erythrocyte 
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aggregation and rouleaux formation. Furthermore, this combination treatment also 
displayed widespread platelet activation and aggregation. 
 
Following this trend, the LBP + SAA and HDL + LBP + SAA incubations both showed 
altered erythrocyte and platelet morphology whereby extensive platelet activation and 
aggregation was observed. These two incubations qualitatively display the greatest 
change in morphology. When qualitatively analysing fibrin clot images, figure 5.3.4.2 
below, it is evident that the exposure of PPP to 30 µg.mL-1 Serum Amyloid A causes clear 
morphological alterations when compared to that of the naive control clots (image A and 
B). The control fibrin clots have thin “spaghetti like” fibrin fibres with large open areas 
between the various fibrin fibres which can be seen in image A and B. In contrast however, 
when analysing the clots formed when exposed to SAA (image C and D), no singular fibrin 
fibres can be seen, instead large dense matted aberrant fibrin areas are seen with little to 
no open areas in the clot. This indicates that SAA is possibly amyloidogenic in nature when 
exposed to PPP.  
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Figure 5.3.2.1. Figure showing representative micrographs taken on the Zeiss MERLIN™ field 
emission scanning microscope of whole blood from Control samples. Micrographs of naïve whole blood 
(image A) as well as the whole blood incubated with HDL (image B), LBP (image C), SAA (image D). 
Furthermore, treatment combinations HDL + LBP (image E), HDL + SAA (image F), LBP + SAA (image 
G) as well as HDL + LBP + SAA (image H). Micrographs were captured at various magnifications using 
high resolution InLens capabilities at 1 kV. 
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Figure 5.3.2.2. Figure showing representative micrographs taken on the Zeiss MERLIN™ field emission scanning microscope of fibrin clots formed from 
naïve control (image A and B) PPP and control PPP exposed to 30 µg.mL-1 Serum Amyloid A (image C and D). Images were captured at 5000X (image A 
and C) as well as 10000X (image B and D) using the high resolution InLens capabilities at 1 kV. 
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5.3.3. Confocal Microscopy Results 
 
Figure 5.3.3.1. Representative fibrin clots from naïve control PPP (image A) and control PPP exposed 
to 30 µg.mL-1 Serum Amyloid A (image B). From channel left to right represents Amytracker 680 (red), 
Amytracker 480 (blue) and Thioflavin T (green) respectively. All images were captured at 63X 
magnification using a 2X2 tile scan on the Carl Zeiss LSM 780 confocal microscope. 
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Figure 5.3.3.2. Graphs displaying coefficient of variation (CV) values extrapolated using Image J 
from fibrin clot confocal micrographs of naïve control PPP (n = 5) and control PPP exposed to 30 
µg.mL-1 Serum Amyloid A. Parametric data (image A and C) was analysed using Welch’s corrected 
t test and is represented as the mean ± SEM whereas non-parametric data (image B) was analysed 
using a Mann-Whitney analysis and is represented as box and whisker plots. Significance is set as 
*p < 0.05; ***p < 0.001 and ****p < 0.0001. 
 
Figure 5.3.3.2. shows that the exposure of 30 µg.mL-1 Serum Amyloid A into control PPP 
induced a significant increase in the amyloid signal of the red Amytracker 680 (p = 0.0452) 
and green Thioflavin T (p = 0.0062) fluorescent channels. No significant changes were 
observed in the blue Amytracker fluorescent signal however a trend (p = 0.0888) was seen. 
Although the population size was low (n = 5), these results seem to correlate well with the 
SEM image observed whereby SAA does in fact induce amyloidogenesis in fibrin fibres.  
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5.4 Discussion 
 
In chapter 4 it was determined that SAA, among various other cytokines, was upregulated 
in T2DM. The initial aim for this chapter was thus to assess the amyloidogenic potential of 
SAA when added to control WB and PPP ex vivo. SAA incubated in control blood produced 
no significant impact on any of the seven viscoelastic parameters, table 5.3.1, that assess 
the efficiency of coagulation. This result indicates that SAA potentially has no significant 
impact on the coagulation cascade, however, Page et al. (2019), using the same SAA 
concentration, 30 µg.mL-1, in a younger healthy female population with a greater sample 
size, found that SAA caused a decrease in the MA and TGG in whole blood thus the clot 
formed was less stable. The same study found significantly elevated MA, MRTG and TGG 
values when the SAA was incubated in PPP of the same population, suggesting that SAA 
produces a fibrin(ogen)-mediated enhancement of the coagulation system, while 
simultaneously inhibiting platelet to fibrin(ogen) interaction however this was not observed 
in the current study. 
 
Assessment of morphological changes induced by physiologically low levels of SAA, figure 
5.3.2.1 Image D, indicates the initial stages of erythrocyte eryptosis and platelet activation 
and platelet to erythrocyte agglutination similarly to what is seen in literature (Page et al., 
2019). In contrast to literature however, platelet hyperactivation and total spreading was 
observed in this study, which may be attributed to the age and health status of the control 
population used in the study. This phenomenon may also be due to the fact that a close 
association between inflammation and thrombosis exists, whereby the pro-inflammatory 
state promotes coagulation and activation of platelets as a protective homeostatic 
mechanism (Esmon, 2005). Furthermore, SAA induced the formation of dense matted 
amyloid deposits in the fibrin clots, figure 5.3.2.2, when compared to the PPP naïve fibrin 
clots. This is in line with Page et al. (2019) who used correlative light and electron 
microscopy (CLEM) to determine whether SAA binds and interacts with soluble and 
circulating plasma molecules, like fibrinogen, therefore inducing structural (amyloidogenic) 
changes. This amyloid fibrin formation was further seen using confocal microscopy and 
amyloid-specific fluorescent markers whereby the fibrin clots incubated with SAA had 
significantly elevated signal, figure 5.3.3.2, in comparison to that of the naïve clots. This 
can again be accredited to SAA binding and interacting with circulating fibrinogen thus 
impacting the autocatalytic formation of insoluble fibrin fibres and hence causing beta-
sheet rich misfolded amyloid regions in the fibrin clots. 
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The second aim of this study was to determine whether HDL, LBP and a combination of 
the two are effective mopping agents to inhibit the effect of SAA on the haematological 
system. It was thought that these two markers would be effective as HDL naturally 
associates with and binds SAA whereas LBP has been a proven effective mopping agent 
in T2DM (Pretorius et al., 2017a). Furthermore, a close link between SAA and LPS exists 
naturally. This notion however proved false as the co-treatment of SAA and HDL, SAA and 
LBP as well as SAA, HDL and LBP all induced increased initiation rates of clot formation, 
table 5.3.1, compared to the naïve control coagulation state. Furthermore, the SAA and 
LBP as well as SAA, HDL and LBP combination groups also altered the clot strength with 
significantly reduced MA values possibly indicating decreased platelet and/or fibrin(ogen) 
interaction. These results were further validated as these same three treatment groups 
caused the greatest alterations in whole blood morphology. The SAA and LBP combination 
and the SAA, HDL and LBP combination groups displayed the greatest impact of platelet 
activity and agglutination indicating the combination groups may indeed impact the platelet 
to fibrin interaction. These findings may be attributed to the binding of SAA to HDL 
inhibiting the anti-inflammatory effects of the lipoprotein (Han et al., 2016), consequently, 
enhancing the adverse effects of SAA on the haematological system. Furthermore, as the 
structure of LBP isn’t fully understood yet, the molecule may be able to bind and interact 
with SAA molecules potentially altering the molecules structure, function or the fibrin(ogen) 
binding capacity thus further enhancing the SAA molecules impact of the haematological 
system, this may be a further way to understand the results obtained in this chapter. 
 
This chapter confirmed that SAA is amyloidogenic in nature and induces the formation of 
dense matted amyloid deposits in fibrin clots. The commonly associated molecule HDL 
and a previously proven mopping agent LBP were not able to effectively mop the effects 
of SAA, in contrast they seemed to further exacerbate the deleterious haematological 
effects of SAA.  
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6. Experimental Study  
 
6.1 Introduction 
 
In this chapter we performed all the experiments on Type II Diabetes Mellitus blood. High 
density lipoprotein was added in vitro to the T2DM blood to determine if this so called 
“good” cholesterol can reverse the hypercoagulable and amyloidogenic state observed in 
T2DM. Furthermore, LPS-binding protein was added in vitro as we know elevated levels 
of circulating LPS is associated with T2DM thus potentially the binding protein may be able 
to “mop” and reverse the detrimental effects of T2DM on the haematological system. The 
aim of this chapter was thus to determine if these two mopping agents are effective in 
removing detrimental haematological effects seen in T2DM. The effects of the added 
molecules were tested via analysis of the efficiency of coagulation as well as determining 
whether the molecules affect whole blood and fibrin morphology.  
 
6.2 Materials and Methods 
 
Material and methods for quantitative markers: 
 
Thromboelastography: 
 
The protocol followed for the TEG is identical to that described in chapter 4. The only 
alteration is that in addition to analysis of naïve whole blood, T2DM blood was exposed to 
HDL, LBP and the combination of the afore mentioned molecules. For a detailed 
description of the exposures please refer to table 3.4. 
 
Material and methods for morphological markers: 
 
Scanning Electron Microscopy  
 
Protocols for both whole blood and fibrin analysis followed was identical to that of chapter 
4. Whole blood morphology analysis was conducted on naïve T2DM blood as well as blood 
exposed to HDL, LBP and the combination of the two discussed in table 3.4. Fibrin clot 
morphology was assessed using naïve T2DM PPP as well as PPP incubated with 30 µg. 
mL-1 HDL. 
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Confocal Microscopy 
 
The protocol followed is identical to the protocol discussed in depth in chapter 4. Naïve 
T2DM fibrin clots as well as fibrin clots of T2DM PPP exposed to 30 µg. mL-1 HDL were 
imaged and analysed. 
 
6.3 Results 
 
 
6.3.1 Thromboelastography Results 
 
Table 6.3.1. Table displaying the 7 viscoelastic parameters assessing efficiency of coagulation in 
whole blood of Type II Diabetes Mellitus participants (n=14). Data was generated using the 
Haemoscope TEG® 5000 Haemostasis Analyser. All samples were incubated with 5 ng.L-1 
Lipopolysaccharide- binding protein (LBP) and HDL 30 µg.mL-1 as well as the combination of the 
two molecules. Incubation of each molecule was 10 minutes per molecule added. Friedman tests 
and one-way ANOVAs were performed with a Dunnett’s Multiple comparison being used to 
compare the mean of each group to that of the mean of the naïve group. Data is presented as the 
mean and interquartile ranges with significance set as *p < 0.05; ***p < 0.001 and ****p < 0.0001.  
 
  
Viscoelastic Parameter 
R-
Value 
(mins) 
K-
Value 
(mins) 
Alpha 
Angle 
(deg) MA (mm) 
MRTG 
(Dyn.cm-
2.s-1) 
TMRTG 
(mins) 
TTG 
(dyn.cm-2) 
T
re
a
tm
e
n
t 
re
g
im
e
 
T2DM
Naïve 
6.06 
[4.43 – 
6.95] 
1.99 
[1.58 – 
2.23] 
69.46 
[65.45 – 
72.83] 
63.84 
[59.28 – 
75.03] 
9.47 
[5.89 – 
10.28] 
8.95 
[7.34 – 
10.32] 
1053.00 
[745.20 – 
1505.00] 
HDL 
5.78 
[4.18 – 
7.75] 
2.21 
[1.50 – 
2.88] 
68.56 
[62.15 – 
73.50] 
63.46 
[56.45 – 
70.95] 
7.99 
[4.62 – 
9.94] 
8.51 
[6.67 – 
10.42] 
972.10 
[649.20- 
1231.00] 
LBP 
5.51 
[3.75 – 
7.08]* 
2.29 
[1.40 – 
3.25] 
67.15 
[58.40 – 
73.75] 
57.67 
[48.18 – 
68.05] 
7.65 
[4.07 – 
9.68] 
8.33 
[5.98 – 
10.75] 
792.60 
[464.00 – 
1073.00] 
HDL + 
LBP 
5.20 
[3.88 – 
6.30] 
*** 
2.43 
[1.28 – 
3.38] 
67.94 
[61.70 – 
75.40] 
57.86 
[51.10 – 
68.60] 
7.87 
[4.15 – 
9.49] 
7.63 
[6.29 – 
8.90]** 
849.20 
[530.80 – 
1102.00] 
 
The experimental study was performed using T2DM (n=14) whole blood collected in 
sodium citrate tubes, the naïve whole blood as well as the whole blood incubated with 
LBP, HDL and the combination of the two molecules was analysed using the TEG to 
analyse the efficiency of coagulation. Table 6.3.1. below indicates that five of the seven 
viscoelastic parameters (K-value, Alpha angle, MA, MRTG and TGG) had no significant 
changes throughout the 3 different treatment groups. Furthermore, the HDL incubated 
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treatment in T2DM whole blood produces no significant effect on any of the seven 
parameters assessed. 
 
In contrast, LBP incubated treatment in the T2DM whole blood, produced a significant 
reduction (p = 0.0252) in the R-value in comparison to that of the T2DM naïve group. This 
reduction indicates that the LBP causes the rate of initial thrombus generation to occur at 
a faster rate than that of the naïve group. Moreover, the HDL+LBP group produced 
significant reductions in the R-Value (p = 0.0006) as well as the time to maximal rate of 
thrombus generation (TMRTG) (p = 0.0015), therefore the combination group causes the 
rate in which the thrombus generates to increase in speed in comparison to the T2DM 
naïve group. 
 
6.3.2 Scanning Electron Microscopy Results 
 
Qualitative analysis of the whole blood SEM results indicates than neither the HDL, LBP 
or the HDL + LBP incubations produced notable changes to the whole blood morphology 
in comparison to the naïve T2DM whole blood. In all four groups, eryptotic erythrocytes 
were images with erythrocyte agglutination. Furthermore, platelet hyperactivity and 
aggregation were seen throughout. 
 
In contrast, the SEM analysis of the fibrin clots showed that the HDL may possibly reduce 
amyloid fibrin(ogen) when incubated in T2DM PPP. This phenomenon can be seen in 
image C and D from figure 6.3.2.2, where although still very dense, individual fibrin fibres 
are distinguishable as well as more open spaces being observed in comparison to that of 
the naïve T2DM fibrin clots. 
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Figure 6.3.2.1. Figure showing representative micrographs taken on the Zeiss MERLIN™ field 
emission scanning microscope of whole blood from Type II Diabetes Mellitus samples. Micrographs 
of naïve whole blood (image A) as well as the whole blood incubated with HDL (image B), LBP 
(image C), as well as the combination of HDL + LBP (image D). Micrographs were captured at 
various magnifications using high resolution InLens capabilities at 1 kV. 
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Figure 6.3.2.2. Figure showing representative micrographs taken on the Zeiss MERLIN™ field emission scanning microscope of fibrin clots formed from 
naïve T2DM (image A and B) PPP and T2DM PPP exposed to 30 µg.mL-1 High Denisty Lipoprotein (image C and D). Images were captured at 5000X 
(image A and C) as well as 10000X (image B and D) using the high resolution InLens capabilities at 1 kV.
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6.3.3 Confocal Microscopy Results 
 
Figure 6.3.3.1. Representative fibrin clots from naïve Type II Diabetes Mellitus PPP (image A) and 
T2DM PPP exposed to 30 µg.mL-1 High Density Lipoprotein (image B). From channel left to right 
represents Amytracker 680 (red), Amytracker 480 (blue) and Thioflavin T (green) respectively. All 
images were captured at 63X magnification using a 2X2 tile scan on the Carl Zeiss LSM 780 
confocal microscope.  
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Figure 6.3.3.2. Graphs displaying coefficient of variation (CV) values extrapolated using Image J 
from fibrin clot confocal micrographs of naïve T2DM PPP (n = 10) and T2DM PPP exposed to 30 
µg.mL-1 High Density Lipoprotein. Parametric data (image A) was analysed using Welch’s corrected 
t test and is represented as the mean ± SEM whereas non-parametric data (image B and C) is was 
analysed using a Mann-Whitney analysis and is represented as box and whisker plots. Significance 
is set as *p < 0.05; ***p < 0.001 and ****p < 0.0001. 
 
 
Figure 6.3.3.2 above shows that amyloid signal in the green Thioflavin T channel was 
significantly reduced in the HDL group, however, no differences were observed in either 
the red Amytracker 680 or blue Amytracker 480 fluorescent channels.   
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6.4. Discussion 
 
The aim of this chapter of the study was to determine whether HDL and LBP are effective 
mopping agents in negating the detrimental haematological effects observed in T2DM. 
This study showed that HDL was able to reduce the fibrin amyloid formation whereby both 
the SEM and confocal analysis showed slight reductions in the amyloid present.  These 
changes are consistent with Zabczyk et al. (2013) who showed that increased HDL was 
associated with improved fibrin clot permeability and lysis and speculated that HDL might 
possibly have an antithrombotic mechanism. 
 
In contrast, the TEG data generated showed that LBP incubation and HDL and LBP co-
incubation surprisingly induced fibrin clot formation to occur at a more rapid rate (table 
6.3.1.). This result conflicts the SEM images and confocal data, possibly implying that 
these molecules are not effective mopping agents in T2DM. These results display 
opposing results obtained by Pretorius et al. (2017a) whereby the incubation of 2 ng.L-1 
significantly reduced amyloid signal in T2DM.  
 
Due to the complexity in the pathophysiology of T2DM, the use of a single target “mopping 
agent” seems to be an infeasible approach to tackle the vast impact of the disease on the 
haematological system. A plethora of cytokines, proteins and signalling pathways are 
altered in this disease (Cefalu, 2009) with various of these already being proved to 
influence the coagulation system and the structure of insoluble fibrin fibres (Bester et al., 
2018, Bester and Pretorius, 2016, Kell and Pretorius, 2015, Page et al., 2019, Pretorius et 
al., 2016a, Pretorius et al., 2017b). Furthermore, the presence of raised glucose levels, 
one of the hallmarks of T2DM, alters the fibrin(gen) structure via glycation (Pieters et al., 
2006) possibly inducing fibrin amyloidogenesis. Additionally, T2DM is a condition 
associated with chronically elevated reactive oxygen species (ROS) (Kaneto et al., 2010), 
molecules that circulating fibrinogen is extremely vulnerable to as the interaction induces 
an altered fibrin(ogen) structure which could further lead to fibrin(ogen) amyloidosis 
(Rosenfeld et al., 2016).  
 
Various other molecules that are altered in T2DM also have the potential to induce amyloid 
fibrin, where the intricate mechanisms on how these various alterations cause the changes 
in the haematological system not being fully understood yet. Consequently, proposing a 
single or multi molecule targeting mopping agent that does not account for the vast 
systemic molecules and mechanistic alterations which may have amyloidogenic potential, 
thus seems an impractical option. 
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7. Conclusion 
 
In this study, using both quantitative and qualitative methods, we confirmed that T2DM is 
associated with chronic low-grade inflammation with an altered pro-inflammatory cytokine 
profile. Furthermore, the APR is chronically activated in T2DM with the presence of 
significantly elevated circulating levels of APPs CRP and SAA. This altered profile induces 
hypercoagulability in the coagulation cascade, alterations in platelet and erythrocyte 
morphology as well causing the insoluble fibrin fibres to be amyloid in nature. These 
changes influence and increase the susceptibility of T2DM individuals to cardiovascular 
complications and stroke. 
 
The study further went on to show that the increased circulating SAA concentrations 
influence the haematological system via hyperactivation of the platelets, inducing eryptosis 
as well as inducing the formation of dense matted amyloid deposits in the insoluble fibrin 
fibres. The study proved that the ex vivo incubation of low physiological levels of SAA in 
healthy control whole blood and platelet-poor plasma induces haematological alterations 
that mimic some of the alterations observed in T2DM. This implicates SAA to these 
changes observed in the disease. Furthermore, due to the alterations observed in the 
fibrin, we can confirm that SAA is indeed amyloidogenic in nature. 
 
Finally, the study aimed at determining whether HDL and LBP were effective mopping 
agents in reversing the detrimental haematological alterations induced by SAA. These two 
molecules especially when co-incubated proved to further the problem whereby 
significantly influencing and increasing the rate of the clotting cascade. Due to the 
complexity of a disease like T2DM whereby the whole cytokine profile and signalling 
pathways are altered, the use of a single molecule mopping agent before further research 
is done to understand amyloid mechanisms seems like an unfeasible option. Despite this, 
ex vivo studies, like the present one, are essential to further the understanding of the 
coagulation system in diseased states as well as advancing the understanding in the use 
of mopping agents as treatment options in future.  
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8. Limitations and Future Recommendations 
 
As with all studies, a greater sample size would be valuable in increasing statistical power. 
This would allow the researcher greater confidence in the data generated, enabling for the 
generation of more viable hypotheses for future studies. Additionally, the age of the 
population used in this study limits the study as finding suitable healthy individuals at such 
advanced ages proved extremely difficult. Further to this, locating and recruiting T2DM 
participants at such an advanced age with no comorbidities is almost impossible. Both of 
which would influence the data generated thus impacting the validity of the study. 
 
A further limitation of this study was that the baseline SAA values were not accounted for 
when the external SAA was added ex vivo. Consequently, the SAA exposed to each 
sample was not fully standardised possibly influencing the results obtained. This limitation 
however was out of the control of the researcher as the exposure of SAA to WB for TEG 
and SEM analysis had to be performed on the day the blood was drawn. In contrast, the 
VPLEX analysis for SAA levels was performed at the end of the study once all blood 
samples had been obtained and stored as PPP. 
 
The T2DM participants in this study were all on various medications which are known to 
influence the coagulation status. Although this was a factor out of the researcher’s control, 
this is a confounding factor that may have influenced the results of the study. Furthermore, 
in-depth details such as the duration of T2DM and history of concomitant medical 
conditions was unclear for the Diabetic participants. Consequently, results obtained may 
be skewed as the duration of disease is an independently associated with microvascular 
complications.  
 
Although limitations exist, the principle researcher is confident that the study was 
performed in good faith and that the results generated from this study are a true reflection 
ex vivo of the haematological system in T2DM in vivo. 
 
My future recommendations to further elevate this study would include: using CLEM to 
determine how SAA, HDL and then binding of the two molecules influence the fibrin clot 
formation, using a purified fibrinogen model and repeating the same exposure with the 
mopping agents to negate any unwanted effects caused by the total altered cytokine profile 
in T2DM, performing the study with a younger healthier population as well as with a 
recently diagnosed unmedicated T2DM population and finally performing various methods 
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which include; fluorescent microscopy, atomic force microscopy, microfluidics and an 
animal model, which would all provide a greater mechanistic understanding of how SAA 
impacts coagulation during inflammation, allowing for the understanding of its value in 
diagnosis and even therapy. Furthermore, quantification of CV values for SEM fibrin clots 
would be a valuable technique which could then be correlated with SAA values to gain a 
greater understanding of the relationship between the two parameters. 
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Appendix B: English informed consent form 
PARTICIPANT INFORMATION LEAFLET AND CONSENT 
FORM 
TITLE OF THE RESEARCH PROJECT: 
Investigating the amyloidogenic potential of serum amyloid a in type II diabetes mellitus 
REFERENCE NUMBER: 
PRINCIPAL INVESTIGATOR: Prof E Pretorius 
ADDRESS: Department of Physiological Sciences, Faculty of Science, 
Stellenbosch University, STELLENBOSCH 
CONTACT NUMBER: 
You are being invited to take part in a research project.  Please take some time to read 
the information presented here, which will explain the details of this project.  Please 
ask the study staff or doctor any questions about any part of this project that you do 
not fully understand.  It is very important that you are fully satisfied that you clearly 
understand what this research entails and how you could be involved.  Also, your 
participation is entirely voluntary and you are free to decline to participate.  If you say 
no, this will not affect you negatively in any way whatsoever.  You are also free to 
withdraw from the study at any point, even if you do agree to take part. 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines for 
Good Clinical Practice and the Medical Research Council (MRC) Ethical Guidelines for 
Research. 
What is this research study all about? 
You are invited to participate in research study conducted by Prof Resia Pretorius.  
This information leaflet is to help you to decide if you would like to participate.  Before 
you agree to take part, you should fully understand what is being involved in this 
research study. Your medical practitioner will explain the reason for the drawing of 
blood.  The drawing of 4 blood tubes will be a part of research study.  First tube will be 
sent to pathology laboratory to determine your inflammatory status by looking at 
inflammatory markers like CRP levels. (An increase in CRP levels may influence the 
shape of the red blood cells, platelets and fibrin) and 3 more tubes will be used for our 
Control (mark with x) 
Cardiovascular disease  (mark with x) 
UNIQUE ETHICS NUMBER: 6399;  
Left-over blood will be stored used for similar 
studies, with clearance numbers: 6329; 1952 
Type 2 diabetes (mark with x) 
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laboratory haematological (blood) analysis using specialized microscopic and 
biochemical analysis.  
The research team members are investigating the physiology and functioning of cells 
and molecules in whole blood. This will be done by using specialized equipment suc 
as the flow cytometer and microscopes that can magnify up to 100 000x (called an 
electron microscope and a fluorescent microscope). We will also look at your blood 
using a nanobiosensors, developed by prof Willie Perold and his research students 
from the Engineering Department.  We will store a part of your sample that is not used, 
for later analysis in similar studies, so that we do not waste samples. 
Why have you been invited to participate? 
We are recruiting either healthy or individuals with inflammation and cardiovascular 
disease, with specific focus on individuals with type 2 diabetes over 18 to participate 
in this study, 
What will your responsibilities be? 
You will donate 4 tubes of blood (20 ml).  You have no responsibilities. 
Will you benefit from taking part in this research? 
There are no personal benefits but results generated from this study will allow researchers 
to determine the physiology of healthy clotting and red blood cell structure and will be used to 
test novel nanobiosensors for blood clotting analysis, constructed by the members of the 
Faculty of Engineering, Stellenbosch University. 
Are there in risks involved in your taking part in this research? 
The Venipuncture (i.e. drawing blood) is normally done as part of routine medical care and 
presents a slight risk and discomfort. Drawing blood may result in a bruise at the puncture site, 
or less commonly swelling of the vein, infection and bleeding from the site. For your protection, 
the procedures will be performed under sterile conditions by your medical practitioner or by a 
trained phlebotomist. 
If you do not agree to take part, what alternatives do you have? 
none 
Who will have access to your medical records? 
There will be access to any medical records only to determine previously obtained 
glucose levels and cholesterol levels.   All information obtained during the course 
of this study is strictly confidential. Data that may be reported in scientific journals 
will not include any information, which identifies you as a patient in this study. We will 
ONLY have your name on this informed consent form but will give your blood tubes a 
dedicated UNIQUE number so that you will not be identified in any way.  Prof Pretorius 
and the team will only use the unique number in the data analysis. Samples that are 
not fully used, will be stored under the unique number for  future (repeat or similar) 
tests. 
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What will happen in the unlikely event of some form injury occurring as a direct 
result of your taking part in this research study? 
Neither you nor your medical scheme will be expected to pay for the study.  During a study-
related injury, the Department of Physiological Sciences/ Prof Pretorius assume no obligation 
to pay for the medical treatment of other injuries. You may discuss this in detail with your 
medical practitioner or Pathology Laboratory who have insurance for injuries that might occur 
during routine blood drawing practices. 
Will you be paid to take part in this study and are there any costs involved? 
No you will not be paid to take part in the study. There will be no costs involved for you, 
if you do take part. 
Is there any thing else that you should know or do? 
➢ You can contact the Health Research Ethics Committee at 021-938 9207 if you
have any concerns or complaints that have not been adequately addressed by
your study doctor.
➢ If you request it, you will receive a copy of this information and consent form for
your own records.
HbA1c levels: 
Cholesterol levels: 
Other medication used: 
Declaration by participant 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled Investigating the amyloidogenic potential of serum amyloid a in 
type II diabetes mellitus. 
I declare that: 
• I have read or had read to me this information and consent form and it is
written in a language with which I am fluent and comfortable.
• I have had a chance to ask questions and all my questions have been
adequately answered.
• I understand that taking part in this study is voluntary and I have not been
pressurised to take part.
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• I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
• I may be asked to leave the study before it has finished, if the study doctor 
or researcher feels it is in my best interests, or if I do not follow the study 
plan, as agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2005. 
 
 
 
 ..............................................................   ........................................................ 
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to 
………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer 
them. 
• I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter 
must sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 
2005. 
 
 
 
 ..............................................................   ........................................................ 
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
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• We encouraged him/her to ask questions and took adequate time to answer
them.
• I conveyed a factually correct version of what was related to me.
• I am satisfied that the participant fully understands the content of this
informed consent document and has had all his/her question satisfactorily
answered.
Signed at (place) ......................…........…………….. on (date) 
…………....……………….. 
 ..............................................................  ........................................................ 
Signature of interpreter Signature of witness 
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Appendix C: Afrikaans informed consent form 
DEELNEMERINLIGTINGSBLAD EN -
TOESTEMMINGSVORM 
TITEL VAN DIE NAVORSINGSPROJEK: 
Ondersoek na die amyloïdogene potensiaal van serumamyloïde A in tipe II diabetes mellitus 
“Investigating the amyloidogenic potential of serum amyloid A in type II diabetes mellitus”  
VERWYSINGSNOMMER: 
HOOFNAVORSER: Prof E Pretorius 
ADRES: Departement Fisiologiese Wetenskappe, Fakulteit Natuurwetenskappe, 
Universiteit Stellenbosch, STELLENBOSCH 
KONTAKNOMMER: 0829295041 
U word uitgenooi om deel te neem aan 'n navorsingsprojek. Lees asseblief hierdie 
inligtingsblad op u tyd deur aangesien die detail van die navorsingsprojek daarin 
verduidelik word.  Indien daar enige deel van die navorsingsprojek is wat u nie ten volle 
verstaan nie, is u welkom om die navorsingspersoneel of dokter daaroor uit te vra.  Dit 
is baie belangrik dat u ten volle moet verstaan wat die navorsingsprojek behels en hoe 
u daarby betrokke kan wees.  U deelname is ook volkome vrywillig en dit staan u vry
om deelname te weier.  U sal op geen wyse hoegenaamd negatief beïnvloed word
indien u sou weier om deel te neem nie.  U mag ook te eniger tyd aan die
navorsingsprojek onttrek, selfs al het u ingestem om deel te neem.
Hierdie navorsingsprojek is deur die Gesondheidsnavorsingsetiekkomitee (GNEK) 
van die Universiteit Stellenbosch goedgekeur en sal uitgevoer word volgens die etiese 
riglyne en beginsels van die Internasionale Verklaring van Helsinki, Suid-Afrikaanse 
Riglyne vir Goeie Kliniese Praktyk en die Etiese Riglyne vir Mediese en Genetiese 
Navorsing van die Mediese Navorsingsraad (MNR) van Suid Afrika. 
Wat behels hierdie navorsingsprojek? 
U word uitgenooi om deel te neem aan navorsingsstudie uitgevoer deur Prof Resia 
Pretorius. Hierdie inligtingsblad is saamgestel om u te help om te besluit of u wil 
deelneem. Voordat u saamstem om deel te neem, moet u ten volle verstaan wat hierdie 
navorsingsstudie behels. Die mediese praktisyn sal aan u die rede vir die trekking van 
Kontrole (merk met ’n x) 
Kardiovaskulêre siekte (merk met ’n x) 
UNIEKE ETIESE NOMMER: 6399 
Oorblywende bloed sal gestoor word vir soortgelyke 
studies, met spoedgetalle: 
6329; 1952 
Tipe 2 diabetes (merk met ’n x) 
Stellenbosch University https://scholar.sun.ac.za
104 
bloed verduidelik. Die trekking van vier bloedbuise sal deel vorm van die 
navorsingstudie. Die eerste buis sal na ‘n patologiese laboratorium gestuur word om u 
inflammatoriese status te bepaal deur na inflammatoriese merkers soos CRP te kyk 
('n verhoging in CRP-vlakke kan die vorm van rooibloedselle, bloedplaatjies en fibrien 
beïnvloed). Die ander drie buise sal gebruik word vir hematologiese (bloed) analises 
in ons laboratorium deur gebruik te maak van gespesialiseerde mikroskopiese en 
biochemiese tegnieke. 
Die navorsingspan van hierdie projek bestudeer die fisiologie en funksionering van 
selle in volbloed, wat bloedplaatjies genoem word. Dit word gedoen deur gebruik te 
maak van gespesialiseerdetoersuting soos die vloeisitometer en  mikroskope wat 'n 
beeld tot 100 000 x kan vergroot (dit word 'n elektronmikroskoop  en 'n fluoreserende 
mikroskoop genoem. Ons sal ook kyk na u bloed met  nanobiosensors, ontwikkel deur 
Prof Willie Perold en sy navorsingsstudente van die Fakulteit Ingenieurswese, 
Universiteit Stellenbosch. Ons sal 'n deel van jou monster stoor wat nie gebruik word 
nie, vir latere analise in soortgelyke studies, sodat ons nie steekproewe mors nie 
Waarom is u genooi om deel te neem? 
Ons werf of gesonde of individue met inflammasie en kardiovaskulêre siekte, met 
spesifieke fokus op individue ouer as 18 jaar met tipe 2-diabetes om aan hierdie studie 
deel te neem, 
Wat sal u verantwoordelikhede wees? 
U sal 4 bloedbuisies (20 ml) bloed skenk. U het geen verantwoordelikhede nie. 
Sal u voordeel trek deur deel te neem aan hierdie navorsingsprojek? 
Daar is geen persoonlike voordele nie, maar resultate wat uit hierdie studie gegenereer 
word, sal navorsers in staat stel om die fisiologie van gesonde bloedstolling en 
rooibloedselstruktuur te bepaal en sal gebruik word om 'n nuwe nano-biosensor vir 
analise van bloedstolling te toets, wat deur die lede van die Fakulteit Ingenieurswese 
ontwikkel is. 
Is daar enige risiko's betrokke by u deelname aan hierdie navorsing? 
Die veneuse punktuur (d.w.s. bloedtrekking) word normaalweg gedoen as deel van 
roetine mediese sorg en veroorsaak geringe risiko en ongemak. Bloedtrekking kan lei 
tot 'n kneusplek by die punksieplek, of minder algemeen, swelling van die aar, of 
infeksie en bloeding van die area. Vir u beskerming sal die prosedures onder steriele 
toestande deur u mediese praktisyn of deur 'n opgeleide bloedlating tegnikus uitgevoer 
word. 
As jy nie saamstem om deel te neem nie, watter alternatiewe het jy? 
Geen. 
Wie sal toegang hê tot u mediese rekords? 
Toegang tot mediese rekords sal slegs gedoen word om voorheen verwerfde 
glukosevlakke en cholesterolvlakke te bekom. Alle inligting wat tydens die studie 
verkry word, is streng vertroulik. Data wat in wetenskaplike vaktydskrifte 
gerapporteer word, sal nie enige inligting bevat wat u as pasiënt in hierdie studie 
identifiseer nie. Ons sal SLEGS u naam op hierdie ingeligte toestemmingsvorm hê, 
maar sal 'n UNIEKE nommer op u bloedbuis aanbring sodat u nie op enige manier 
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geïdentifiseer sa kan word nie. Prof Pretorius en haar span sal slegs die unieke 
nommer tydens data-analise gebruik. Monsters wat nie ten volle gebruik word nie, sal 
onder die unieke nommer vir toekomstige (herhalende of soortgelyke) toetse gestoor 
word. 
Wat sal gebeur in die onwaarskynlike geval dat enige vorm van besering 
plaasvind as 'n direkte gevolg van u deelname aan hierdie navorsingstudie? 
Daar sal nie van u of u mediese skema verwag word om vir die studie te betaal nie. 
Tydens 'n studieverwante besering aanvaar die Departement Fisiologiese 
Wetenskappe/ Prof Pretorius geen verpligting om te betaal vir mediese behandeling 
van ander beserings nie. U kan dit in detail bespreek met u mediese praktisyn of 
patologiese laboratorium wat versekering het vir beserings wat tydens roetine 
bloedtrekkings mag voorkom. 
Sal u finansieel word om aan hierdie studie deel te neem en is daar enige koste 
daaraan verbonde? 
Nee, u sal nie betaal word om deel te neem aan die studie nie. Daar sal ook geen 
koste vir u wees as u deelneem nie. 
Is daar enige iets anders wat u moet weet of doen? 
➢ U kan die Gesondheidsnavorsingsetiekkomitee by 021 938 9207 kontak indien
u enige besorgdheid of klagtes het wat nie behoorlik deur die studieleier
aangespreek is nie.
➢ As u dit aanvra, sal u 'n afskrif van hierdie inligting- en toestemmingsvorm vir u
eie rekords ontvang.
HbA1c vlakke: 
Cholesterolvlakke: 
Verklaring deur deelnemer 
Met die ondertekening van hierdie dokument onderneem ek, .............................. 
....…….....................……….....……... om deel te neem aan ’n navorsingsprojek getiteld 
'n Nuwe nano-biosensor vir die opsporing van aktivering van bloedplaatjies in 
inflammasie en kardiovaskulêre siektes, met spesifieke fokus op tipe 2-diabetes 
deur die aktiveringskapasiteit van vyf bloedplaatjie-agoniste te ondersoek. 
Ek verklaar dat: 
• Ek hierdie inligtings- en toestemmingsvorm gelees het of aan my laat
voorlees het en dat dit in ’n taal geskryf is waarin ek vaardig en gemaklik
mee is.
• Ek geleentheid gehad het om vrae te stel en dat al my vrae bevredigend
beantwoord is.
• Ek verstaan dat deelname aan hierdie navorsingsprojek vrywillig is en dat
daar geen druk op my geplaas is om deel te neem nie.
• Ek kan kies om die studie te eniger tyd te verlaat en sal op geen manier
gepenaliseer of benadeel word nie.
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• Ek mag gevra word om die studie te verlaat voordat dit klaar is, indien die studie
dokter of navorser voel dat dit in my beste belang is, of as ek nie die studieplan
volg soos ooreengekom nie.
Geteken te (plek)  .............................................. op (datum)  ........................................ 
 ..............................................................  ........................................................ 
Handtekening van deelnemer Handtekening van getuie 
Verklaring deur navorser 
Ek (naam) ………………………………………………… verklaar dat: 
• Ek die inligting in hierdie dokument verduidelik het aan 
..........................................................................……….. 
• Ek hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik het
om dit te beantwoord.
• Ek tevrede is dat hy/sy al die aspekte van die navorsingsprojek soos hierbo
bespreek, voldoende verstaan.
• Ek ’n tolk gebruik het/nie ’n tolk gebruik het nie.  (Indien ’n tolk gebruik is,
moet die tolk die onderstaande verklaring teken.)
Geteken te (plek)  .............................................. op (datum)  ........................................ 
 ..............................................................  ........................................................ 
Handtekening van navorser Handtekening van getuie 
Verklaring deur tolk 
Ek (naam) ………………………………………………… verklaar dat: 
• Ek die navorser (naam) ………..........................................…………………. 
bygestaan het om die inligting in hierdie dokument in Engels/Xhosa aan 
(naam van deelnemer) …….....…………………......................... te 
verduidelik. 
• Ons hom/haar aangemoedig het om vrae te vra en voldoende tyd gebruik
het om dit te beantwoord.
• Ek ’n feitelik korrekte weergawe oorgedra het van wat aan my vertel is.
• Ek tevrede is dat die deelnemer die inhoud van hierdie dokument ten volle
verstaan en dat al sy/haar vrae bevredigend beantwoord is.
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Geteken te (plek)  .............................................. op (datum)  ........................................ 
 ..............................................................  ........................................................ 
Handtekening van tolk Handtekening van getuie 
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Appendix D: Turnitin report 
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